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Abstract 
Hematopoietic stem cell transplantation (HSCT) is used to treat many non-malignant 
and malignant pediatric diseases. A growing number of survivors of pediatric HSCT 
enter adulthood and middle age. There is increasing evidence that exposure to 
irradiation and DNA damaging agents in childhood accelerates aging. Increased risk 
of premature ovarian failure, early atherosclerosis and frailty has been reported 
among adult survivors of childhood cancer. Less is known about the effects of 
pediatric HSCT on long-term organ functions and aging. 
 
The first part of this thesis was designed to retrospectively evaluate the effects of 
allogeneic HSCT in childhood and adolescence on long-term ovarian function. The 
second part was designed to investigate cardiovascular risk factors, endothelial 
function, arterial morphology and stiffness, left ventricular (LV) mass and function, 
and physical fitness and frailty in adult and adolescent survivors of high-risk 
neuroblastoma (HR NBL) after autologous HSCT.  
 
The objective of this thesis was to study whether long-term survivors of pediatric 
HSCT show signs of premature vascular, reproductive and physical aging and 
whether these signs of aging associate with HSCT therapy, cardiovascular health, 
markers of inflammation or telomere length. 
 
The first study population included a cohort of 92 female long-term survivors who 
were less than 20 years of age when receiving allogeneic HSCT at the Children’s 
Hospital, Helsinki University Hospital, Helsinki, Finland, or Karolinska University 
Hospital Huddinge, Stockholm, Sweden, between 1978 and 2000. The follow-up 
data were collected from medical records and included signs of spontaneous puberty, 
age at menarche, the use of hormone replacement therapy, pregnancies, and 
information about pubertal or postpubertal serum FSH levels.  
 
The second study population included the Finnish national cohort of 19 (79%) very 
long-term HR NBL survivors after autologous HSCT, born in 1996 or earlier and 
treated at any of the five University Hospitals in Finland between 1980 and 2000. 
One high-risk retinoblastoma survivor treated similarly was included as well. 
Twenty healthy individually age- and sex-matched controls were recruited as 
controls. Clinical examinations included anthropometrics, blood samples, 24h 
ambulatory blood pressure (BP), very-high-resolution vascular ultrasound, 3D 
echocardiography and Tissue Doppler Imaging cardiac ultrasounds, flow-mediated-
dilatation test, body composition measured with dual-energy X-ray absorptiometry, 
physical performance tests, questionnaire and interview. Medical history was 
collected from medical records. 
Abstract 
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The first study showed that older age at HSCT and total body irradiation and 
busulfan-based conditionings were risk factors for early ovarian aging. Leukemia 
survivors with previous cranial radiotherapy or transplanted after disease relapse 
were at high risk of premature ovarian failure. The second study showed a higher 
frequency of carotid and femoral arterial plaques, thickened intima layer in radial 
and femoral arteries, increased carotid intima-media thickness and stiffness, 
decreased carotid compliance and arterial lumen diameters in brachial and femoral 
arteries and increased cardiovascular risk profile in the HR NBL survivors when 
compared to the controls. The third study showed that the HR NBL survivors had 
increased LV mass and decreased systolic and diastolic LV function when compared 
to the controls. Poor LV function associated with cardiac biomarkers, poor physical 
performance and increased BP. The fourth study showed shorter telomere length and 
increased frequency of frailty phenotype including decreased lean mass, slowness, 
weakness and low physical activity among the HR NBL survivors when compared to 
the age-matched controls. The frailty phenotype associated with cardiovascular 
health and chronic inflammation. 
 
In conclusion, our study shows that adult and adolescent survivors after HSCT at a 
young age are at risk of early reproductive and vascular aging and frailty. The 
survivors of pediatric HSCT require regular follow-up in adulthood and 
interventions for declining ovarian function, cardiovascular risk factors, high BP, 
subclinical signs of atherosclerosis and decreased cardiac function. Since lifestyle 
choices can influence cardiovascular health and frailty status, a healthy lifestyle, 
non-smoking and physical activity should be advocated among all survivors who 
have received HSCT in childhood. 
 9 
Tiivistelmä 
Hematopoieettista kantasolusiirtoa käytetään hoitona useissa hyvän- ja 
pahanlaatuisissa taudeissa. Yhä useampi kantasolusiirtohoidetuista potilaista paranee 
ja saavuttaa aikuisiän. Ensimmäiset kantasolusiirtohoidetut potilaat ovat pian keski-
ikäisiä. Altistuminen lapsena DNA:ta vaurioittavalle säde- tai solunsalpaajahoidolle 
altistaa ennenaikaiselle vanhenemiselle. Aikuistuneilla lapsisyöpäpotilailla on 
todettu verrokkeja useammin ennenaikaisia vaihdevuosia, verisuonien vanhenemista 
ja raihnaisuutta. Tietoa hematopoieettisen kantasolusiirtohoidon pitkäaikaisista 
vaikutuksista elinten toimintaan ja vanhenemiseen on toistaiseksi vähän. 
 
Tutkimuksen ensimmäisen osan tavoitteena oli selvittää pitkäaikaista 
munasarjatoimintaa lapsuus- ja nuoruusiässä saadun allogeenisen kantasolusiirron 
jälkeen. Tutkimuksen toisen osan tavoitteena oli selvittää sydän- ja 
verisuoniriskitekijöiden esiintymistä, valtimoiden rakennetta ja jäykkyyttä, 
endoteelitoimintaa, vasemman kammion massaa ja toimintaa sekä fyysistä kuntoa ja 
raihnaisuutta aikuisiässä korkean riskin neuroblastoomasta selvinneillä. Näillä 
tutkimuksilla pyrittiin selvittämään, todetaanko lapsena kantasolusiirtohoidon 
saaneilla ikäverrokkeja useammin raihnaisuutta tai suonten tai sukurauhasten 
vanhenemista. Pyrimme lisäksi arvioimaan raihnaisuuden ja kardiovaskulaarisen 
vanhenemisen yhteyttä sydän- ja verisuoniterveyteen, tulehdukseen ja telomeerin 
pituuteen. 
 
Ensimmäinen tutkimuskohortti käsitti 92 parantunutta naispotilasta, jotka olivat alle 
20-vuotiaita saadessaan allogeenisen kantasolusiirron Lastenklinikalla Helsingin 
yliopistollisessa sairaalassa Helsingissä tai Karoliinisessa yliopistosairaalassa 
Tukholmassa vuosina 1978-2000. Tiedot puberteetista, kuukautisten alkamisiästä, 
hormonikorvaushoidon tarpeesta, raskauksista ja seerumin FSH-tasoista kerättiin 
sairaskertomuksista.  
 
Toinen potilasryhmä oli vuosina 1980-2000 Suomessa hoidettu kansallinen kohortti, 
joka koostui 19:stä (79 % koko kohortista) autologisella kantasolusiirrolla korkean 
riskin neuroblastoomasta parantuneesta potilaasta. Lisäksi tutkittiin yksi samaa 
hoitoa saanut korkean riskin retinoblastoomasta parantunut potilas sekä 20 tervettä 
ikä- ja sukupuolivakioitua verrokkia. Kliininen tutkimus sisälsi pituuden ja painon 
mittaukset, verikokeet, 24 tunnin verenpainemittauksen, valtimoiden korkeataajuisen 
ultraäänitutkimuksen, sydämen 3D- ja kudosdopplerultraäänen, endoteelifunktion 
tutkimuksen, kehon koostumuksen mittauksen DXA-laitteella, kuntotestit sekä 
kyselykaavakkeen ja haastattelun. Sairaushistoria kerättiin sairaskertomuksista. 
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Ensimmäisessä tutkimuksessa todettiin, että korkeampi ikä kantasolusiirron hetkellä 
ja koko kehon sädetys tai busulfan-pohjainen esihoito ennustivat 
munasarjatoiminnan ennenaikaista loppumista ja munasarjojen vanhenemista. 
Leukemiasta parantuneilla pään sädehoito ennen kantasolusiirtoa tai kantasolusiirto 
taudin uusimisen jälkeen lisäsivät riskiä munasarjojen toiminnan hiipumiseen. 
Toisessa tutkimuksessa todettiin, että korkean riskin neuroblastoomapotilaiden 
valtimoissa todetaan useammin plakkeja, paksuuntunut intima, alentunut valtimoiden 
joustavuus, pienentynyt läpimitta sekä enemmän sydän- ja verisuoniriskitekijöitä 
kuin ikävakioiduilla verrokeilla. Kolmannessa tutkimuksessa todettiin, että korkean 
riskin neuroblastoomapotilailla vasemman kammion massa on lisääntynyt, 
systolinen ja diastolinen toiminta on huonontunut, sydämen merkkiaineet veressä 
ovat koholla ja fyysinen suorituskyky on alentunut verrattuna ikävakioituihin 
verrokkeihin. Lisäksi todettiin yhteys kohonneen verenpaineen ja lisääntyneen 
vasemman kammion massan välillä. Neljännessä tutkimuksessa todettiin, että 
korkean riskin neuroblastoomapotilailla on lyhyemmät telomeerit kuin 
ikävakioiduilla verrokeilla, minkä lisäksi heillä todetaan useammin raihnaisuuteen 
liittyviä löydöksiä, kuten vähentynyttä lihasmassaa, hitautta, heikkoutta ja vähäistä 
fyysistä aktiivisuutta. Raihnaisuus liittyi huonoon sydän- ja verisuoniterveyteen sekä 
krooniseen tulehdukseen. 
 
Johtopäätöksenä todetaan, että lapsuuden kantasolusiirtohoitoon liittyy riski 
verisuonten ja sukurauhasten ennenaikaiseen vanhenemiseen ja raihnaisuuteen. 
Lapsena kantasolusiirtohoidon saaneita tulee seurata säännöllisesti aikuisiässä 
mahdollisesti heikkenevän sydän- ja munasarjatoiminnan, kohonneen verenpaineen 
ja kehittyvän ateroskleroosin vuoksi. Koska elämäntapavalinnoilla voidaan vaikuttaa 
sydän- ja verisuoniterveyteen ja raihnaisuuteen, tulee kaikkia lapsuudessa 
kantasolusiirron saaneita aktiivisesti ohjata terveellisiin elämäntapoihin, tupakoinnin 
välttämiseen ja kuntoiluun. 
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Abbreviations 
24DIA% proportion of 24-hour diastolic blood pressure exceeding limits 
16SDI 16-segment dyssynchrony index 
24SYS mean 24-hour systolic blood pressure 
24SYS% proportion of 24-hour systolic blood pressure exceeding limits 
3DE three-dimensional echocardiography 
ABPM ambulatory blood pressure measurement 
ALL acute lymphoblastic leukemia 
AML acute myeloid leukemia 
BMI body mass index 
BP blood pressure 
BSA body surface area 
CNS central nervous system 
CRT cranial radiotherapy 
ECG electrocardiogram 
EDV end-diastolic volume 
EF  ejection fraction 
ESV end-systolic volume 
FMD flow-mediated dilatation 
FSH follicle stimulating hormone 
GHbA1c glycosylated hemoglobin A1c 
GVHD graft-versus-host disease 
fTBI fractioned total body irradiation 
HDTx high-dose therapy 
HR NBL high-risk neuroblastoma 
hsCRP high sensitivity C-reactive protein 
HSCT hematopoietic stem cell transplantation 
IGF-1 insulin-like growth factor 1 
IMT intima-media thickness 
LD lumen diameter 
LV left ventricle 
LVM left ventricular mass 
LVMI left ventricular mass index 
NBL neuroblastoma 
proPNB N-terminal pro-B-type Natriuretic Peptide 
PW Pulse Wave Doppler 
PW E early mitral peak flow velocity 
RT radiotherapy 
SAA severe aplastic anemia 
SD standard deviation 
SDS standard deviation score 
sTBI single fraction total body irradiation 
TBI total body irradiation 
TDI Tissue Doppler Imaging 
TDI E’ early diastolic myocardial relaxation velocity 
TDI S’ systolic myocardial velocity 
TNF tumor necrosis factor 
TNI total nodal irradiation 
VHRU very-high-resolution ultrasound 
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1 Introduction 
Hematopoietic stem cell transplantation (HSCT) is used in many high-risk malignant 
and non-malignant diseases affecting hematopoietic or immune systems. Patients 
with metastatic, refractory, or recurrent solid tumors are treated with intensive high-
dose therapies (HDTx) with autologous HSCT as a stem cell support. In Finland, 
approximately 40 children receive HSCT every year.  
HSCT was first investigated as a protective treatment for those exposed to accidental 
high-dose irradiation, such as atomic bomb exposure. In the 1950s total body 
irradiation (TBI) was shown to eradicate leukemic hematopoietic cells and HSCT 
was introduced as a treatment in hematologic malignancies. First HSCTs were 
performed between identical twins (Thomas et al. 1959). TBI by itself was not 
proven to be good in long-term leukemia control, and cyclophosphamide was 
introduced in combination with TBI in the late 1970s.  
Dose intensification of conditioning regimens and exploring new drugs to reduce the 
risk of relapse or rejection were under research in the 1980s. HDTx with autologous 
HSCT support was introduced to increase dose intensity and response in 
chemosensitive tumors. In Finland, single dose TBI (sTBI) was replaced with 
fractionated TBI (fTBI) in 1984 to reduce toxicity. 
In the 1990s, standard, intensified and reduced conditioning regimens were 
introduced. Patients with low-risk disease but at high risk for treatment-related 
toxicity were given different combinations of drugs and radiotherapy (RT) than 
patients with high-risk disease and low risk for toxicity. Due to the increasing 
evidence of TBI-related long-term toxicity and adverse effects on growth, endocrine 
and other organ systems, TBI was no longer used to treat small children. 
During the 2000s effective primary therapies, with conventional methods, have 
significantly reduced the use of HDTx in high-risk solid tumors and the use of 
allogeneic HSCT in the first leukemia remission. Indications of allogeneic HSCT 
have become wider and it is increasingly used to treat immunodeficiencies, 
metabolic diseases and hemoglobinopathies. The future development of HSCT 
therapy aims at the further individualization of conditioning therapies, novel graft 
product engineering, and improved graft-versus-host disease (GVHD) prophylaxis. 
Less treatment-related morbidity and improved quality of life after HSCT are other 
significant future aims. Nearly all children treated with HSCT will experience at 
least one late effect (Wilhelmsson et al. 2015). Information from long-term studies is 
emerging, suggesting a significant rise in organ dysfunctions with increasing age. 
Any acute major life event, such as severe illness, is known to accelerate human 
aging. Suboptimal lifestyle choices may further speed up this process. Young adult 
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childhood cancer survivors have been shown to be at an increased risk of frailty 
(Ness et al. 2015) but the frequency of frailty after pediatric HSCT is not known. 
This study was initiated to investigate the frequency and etiology of ovarian failure, 
vascular aging and frailty among adult survivors of HSCT in childhood.  
 
 
 
 
 
 
 
 
 
 
“A Man is as Old as His Arteries” 
 
Thomas Sydenham, M.D. (1624-1689) 
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2 Review of the Literature 
2.1 Hematopoietic Stem Cell Transplantation in 
Childhood 
 
 
Figure 1. Patient receiving hematopoietic stem cells (HSC) from a healthy donor 
in allogeneic hematopoietic stem cell transplantation (HSCT) after high-
dose therapy (HDTx) with or without total body irradiation (TBI). 
2.1.1 Allogeneic HSCT 
In severe hematological diseases, the purpose of allogeneic HSCT is to replace the 
defective bone marrow with a healthy one, and in malignant hematological diseases, 
to harness alloimmunity for the prevention of disease recurrence. In allogeneic 
HSCT, patients are treated with chemo- or radiotherapy in order to cause bone 
marrow failure and to destroy unwanted cancer cells. Stem cells from a closely 
matched donor are infused and bone marrow is replaced (Figure 1). The donor can 
be a sibling, other relative or an unrelated donor from registries. The stem cell source 
can be bone marrow, peripheral blood or cord blood. In general, criteria that have to 
be taken into account in donor selection are human leukocyte antigen type, 
cytomegalovirus status, gender, health status, and donor age. Indications for 
allogeneic HSCT include hematological malignancies (Acute Lymphoblastic 
Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, 
Myelodysplasia), malignant solid tumors (Non-Hodgkin Lymphoma), non-malignant 
hematological diseases (Severe Aplastic Anemia (SAA), Osteopetrosis, Diamond-
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Blackfan Anemia, Fanconi Anemia, Sickle Cell Anemia, Thalassemia Major, 
Chronic Granulomatous Disease), immune deficiencies (Severe Combined 
Immunodeficiencies, Wiskott-Aldrich syndrome, X-Linked Lymphoproliferative 
Disease) and inborn errors of metabolism (Lysosomal Storage Diseases). 
 
 
Figure 2. Patient receiving his or her own hematopoietic stem cells (HSC) 
collected before high-dose therapy (HDTx) with or without total body 
irradiation (TBI) in autologous hematopoietic stem cell transplantation 
(HSCT). 
2.1.2 Autologous HSCT 
In autologous HSCT, the patient receives his or her own cryopreserved bone marrow 
stem cells or CD34+ stem cells collected from peripheral blood before intensive 
therapy (Figure 2). Stem cells are infused to support hematological recovery after 
HDTx. HDTx is used to increase dose intensity and response in chemosensitive 
tumors. In previous decades, tandem or even triple HDTx have been used. Current 
indications for using autologous HSCT are high-risk neuroblastoma (HR NBL), 
Hodgkin’s disease, germ cell tumors and Ewing sarcoma. HDTx is also used to 
avoid irradiation in infants and small children and in bilateral Wilms’ tumor. 
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2.1.3 HSCT in Treatment of High-Risk Neuroblastoma 
Neuroblastoma (NBL) is the most common extracranial malignant solid tumor in 
pediatric patients. NBL is a disease of the sympaticoadrenal lineage of the neural 
crest. Tumors arise from the adrenal medulla, cervical, thoracic or lumbar areas. 
Disseminated disease can be found in cortical bone, bone marrow, liver, skin, lymph 
nodes, lungs and the central nervous system (CNS). Staging of NBL is based on the 
International Neuroblastoma Staging System (INSS) (Brodeur et al. 1988, Brodeur et 
al. 1993) and International Neuroblastoma Risk Group Staging System (INRG) 
(Cohn et al. 2009) (Table 1). The annual incidence of NBL in Finland is 
approximately nine new cases per year (Madanat-Harjuoja et al. 2014), which 
corresponds to an incidence of nine per million children. Approximately one-half of 
the NBL patients present with high-risk features, which are: age over 18 months at 
diagnosis, stage 4 disease, MYCN amplification and stroma-poor histology in 
Shimada classification. All stage 4 NBL patients over 18 months at diagnosis, 
patients with NBL with MYCN amplification (except stage 1 and stage 4S) and 
those with stage 3 NBL with unfavorable histology are regarded to have HR NBL.  
The treatment of HR NBL with intensive induction chemotherapy, surgery, RT, 
single or multiple HDTx with autologous HSCT and post-transplant therapy with 
isotretinoin (13-cis retinoic acid) therapy has resulted in event-free survival up of to 
40-50%. However, more than half of the patients experience disease recurrence. 
Myeloablative therapy has shown to improve event-free survival (Saarinen-Pihkala 
et al. 2012, Yalcin et al. 2015). However, for overall survival, there is currently no 
evidence of an improving effect when additional follow-up data are included (Yalcin 
et al. 2015). A possible explanation can be that treatment options for progressive 
disease or relapse are decreased in patients who have received myeloablative 
therapy, or there is increased mortality in HSCT-related late effects. In the newest 
HR NBL treatment protocols novel immunotherapies have been introduced, 
including anti-GD2 monoclonal antibody, granulocyte-macrophage colony-
stimulating factor (GM-CSF) and aldesleukin (interleukin-2). 
 
 
 
 
 
 
 
 
 17 
Table 1. Neuroblastoma staging according to INSS and INRG systems. 
INSS classification system 
Stage 1 
Localized tumor with complete gross excision, with or without microscopic residual 
disease; representative ipsilateral lymph nodes negative for tumor microscopically 
(nodes attached to and removed with the primary tumor may be positive). 
Stage 2A 
Localized tumor with incomplete gross excision; representative ipsilateral 
nonadherent lymph nodes negative for tumor microscopically. 
Stage 2B 
Localized tumor with or without complete gross excision, with ipsilateral 
nonadherent lymph nodes positive for tumor. Enlarged contralateral lymph nodes 
must be negative microscopically. 
Stage 3 
Unresectable unilateral tumor infiltrating across the midline, with or without 
regional lymph node involvement; or localized unilateral tumor with contralateral 
regional lymph node involvement; or midline tumor with bilateral extension by 
infiltration (unresectable) or by lymph node involvement. 
Stage 4 
Any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, 
liver, skin, and/other organs (except as defined for stage 4S). 
Stage 4S 
Localized primary tumor (as defined for stage 1, 2A, or 2B), with dissemination 
limited to skin, liver, and/or bone marrow (limited to infants, 1 year of age). 
INRG staging system 
L1 
Localized tumor not involving vital structures as defined by the list of IDRFs and 
confined to one body compartment. 
L2 Loco-regional tumor with the presence of one or more IDRFs. 
M Distant metastatic disease (except stage MS). 
MS 
Metastatic disease in children younger than 18 months with metastases confined to 
skin, liver, and/or bone marrow. 
IDFR, Image Defined Risk Factors; INRG, International Neuroblastoma Risk Group Staging System; 
INSS, International Neuroblastoma Staging System 
Modified from detailed criteria of staging (Brodeur et al. 1988, Brodeur et al. 1993, Cohn et al. 2009). 
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2.2 Late Effects after HSCT in Childhood 
2.2.1 Acute Complications after HSCT 
Acute complications after HSCT include conditioning regimen-related toxicity, 
infections and GVHD. Acute toxicity includes sinusoidal obstruction syndrome, 
veno-occlusive disease in the liver, hemorrhagic cystitis and transplant-associated 
microangiopathy. After HSCT, the recipient’s immune system is reconstituted. 
Patients are at risk for bacterial infections, viral infections, infections with 
respiratory viruses, fungal infections and reactivation of herpes viruses, such as 
cytomegalovirus. Acute and chronic GVHD results from alloreactivity between 
donor and recipient. Acute GVHD develops after a “cytokine storm”, usually one to 
14 weeks after allogeneic HSCT. Chronic GVHD is usually defined when GVHD 
occurs after day 100 post-transplant. The classic target organs are the skin, liver, and 
gastrointestinal tract (Ferrara et al. 2009). 
2.2.2 Late Complications of HSCT 
2.2.2.1 Chronic GVHD, Late Infections, and Immune Deficiency 
Chronic GVHD with immune deficiency is the primary cause of transplant-related 
mortality late after HSCT and contributes directly or indirectly to most non-
malignant complications. The incidence of chronic GVHD after sibling-matched 
related and unrelated transplantation lies between 27% to 50% and 42% to 72% (Lee 
et al. 2002). Higher donor and recipient age, prior acute GVHD, use of alloimmune 
female donors, type of GVHD prophylaxis, and history of recipient herpes virus 
infection are factors which further increase the incidence of chronic GVHD (Socie et 
al. 2003, Lee et al. 2002). Skin changes, extensive skin involvement, elevated 
bilirubin, progressive onset, thrombocytopenia, and prior steroid 
refractory/dependent acute GVHD are known to predict poor survival of patients 
suffering from chronic GVHD (Lee et al. 2002). 
2.2.2.2 Late Ocular Effects 
Ocular complications include keratoconjunctivitis sicca, conjuctival GVHD, 
cataracts, corneal infections, microvascular retinopathy, optic disk edema, 
hemorrhagic complications and infectious retinitis (Coskuncan et al. 1994). The 
incidence of cataract may reach up to 80% in long-term follow-up (Socie et al. 
2003). Posterior segment complications have been seen in 13% of the patients 
(Coskuncan et al. 1994). 
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2.2.2.3 Pulmonary Late Effects 
Sensitivity to cytotoxic agents and irradiation, infections, and immune-mediated lung 
injury associated with GVHD are the factors contributing to late pulmonary 
complications. These complications affect 15% to 40% of transplanted patients and 
include abnormal pulmonary function tests with loss of lung volume and diffusing 
capacity and chronic obstructive pulmonary disease (Cerveri et al. 2001, Soubani et 
al. 1996). 
2.2.2.4 Late Liver Complications 
Late liver complications include chronic hepatitis and iron overload. Liver biopsies 
show hemosiderosis in most patients (90%) when performed early after HSCT (Iqbal 
et al. 1996). A correlation exists between iron accumulation and persistent hepatic 
dysfunction, presumably as a consequence of intracellular iron and the toxic effect of 
free radicals. 
2.2.2.5 Late Complications of Bones and Joints 
TBI, previous chemotherapy and hypogonadism have been identified as risk factors 
for bone loss and osteoporosis (Schimmer et al. 2000, Weilbaecher 2000). 
Osteopenia and osteoporosis are both characterized by an impaired bone mass and 
increased vulnerability to bone fracture. The incidence of avascular necrosis varies 
from 2% to 11% after HSCT (Fink et al. 1998, Socie et al. 1994, Socie et al. 1997). 
The hip is the affected site in more than 80% of the cases. Other locations include 
the knee, wrist, and ankle. 
2.2.2.6 Dental Late Effects 
Conditioning regimens including TBI can result in severe damage to the dental 
enamel organ and developing teeth among 80% of the patients (Dahllof et al. 1988, 
Pajari & Lanning 1995), including hypoplasia and microdontia of the crowns and 
thinning of the roots of permanent teeth (Uderzo et al. 1997). 
2.2.2.7 Endocrine Function after HSCT 
Thyroid dysfunction is one of the most frequent late complications of HSCT (43% of 
patients), including overt and subclinical-compensated hypothyroidism and 
autoimmune thyroid disease (Sklar et al. 1982). The majority of cases of overt 
hypothyroidism following HSCT are due to direct damage to the thyroid gland by 
TBI. 
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Growth deficiency is more evident in children who receive transplants at a younger 
age or have received RT (Shinagawa et al. 2001). The growth impairment is 
estimated to be approximately one height standard deviation score (SDS) (equivalent 
to 6 cm) compared with the mean genetic height (Cohen et al. 1999a, Cohen et al. 
1999b, Shinagawa et al. 2001). On the other hand, children who are conditioned 
without TBI usually grow normally. Posttransplantation factors such as GVHD and 
treatment with steroids may have an influence on growth failure in childhood. 
2.2.2.8 Testicular Failure 
Testicular failure is a common (70% of patients) long-term consequence of HSCT 
(Anserini et al. 2002). The major cause of gonadal damage leading to 
hypergonadotropic-hypogonadism is conditioning with TBI. The testicular germinal 
epithelium where spermatogenesis occurs is more vulnerable to radiation and 
chemotherapy than the Leydig cells where testosterone secretion occurs. Therefore, 
while spermatogenesis is reduced or absent, testosterone levels are usually normal. 
The probability for recovery of spermatogenesis after HSCT is associated with the 
type of conditioning therapy, the age of the patient, the time interval since 
transplantation, and the absence of chronic GVHD (Anserini et al. 2002, Rovo et al. 
2006). 
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Table 2. Evidence of ovarian damage and reproductive potential after HSCT 
and cancer treatment in childhood. 
Author and 
Year 
Patients, 
n 
Follow-up time Cohort Study Findings 
Armenian et 
al, 2011 
7,207/145 5 years 
Pediatric 
auto/alloHSCT 
Relative risk of OF 
9.3/39.3 in HSCT 
survivors vs. only 
conventionally 
treated/controls. 
Bakker et al, 
2000 
19 8 years Pediatric alloHSCT 
(6/10) 60% of those 
prepubertal at HSCT 
had spont puberty and 
menarche. 
Borgmann-
Staudt et al, 
2012 
138 6 years Pediatric alloHSCT 
Older age and Bu risk 
factors for OF. 
Bresters et al, 
2014 
109 7 years Pediatric HSCT 
OF associated with 
older age at HSCT and 
Bu conditioning. 
Sanders et al, 
1988 
43/144 >1 year 
Pediatric and adult 
alloHSCT, 
SAA/leukemia 
After Cy ovary 
recovers in those 
younger at HSCT and 
some old survivors but 
after TBI only few 
young at HSCT 
recovered. 
Sanders et al, 
1996 
708 3 years 
Pediatric and adult 
alloHSCT 
16% recovered 
ovarian function and 
5% became pregnant 
among postpubertal 
women. 
Sanders et al, 
2011 
63 22 years 
Pediatric alloHSCT, 
SAA 
Normal puberty, 
menarche, fertility. 
Bu, busulfan; Cy, cyclophosphamide; HSCT, hematopoietic stem cell transplantation; HRT, hormone 
replacement therapy; OF, ovarian failure; SAA, severe acute anemia; TBI, total body irradiation 
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2.2.2.9 Premature Menopause and Ovarian Failure 
The oocytes are very sensitive to HSCT therapy. The age at transplantation is of 
major importance. The younger the age, the better the chances for gonadal recovery 
(Table 2). Ovarian failure in postpubertal girls is usually irreversible, whereas in 
prepubertal girls, there is a possibility for a subsequent spontaneous recovery and 
achievement of spontaneous menarche (Borgmann-Staudt et al. 2012, Spinelli et al. 
1994, Sanders et al. 1988, Bresters et al. 2014). The physiological decline in the 
ovarian reserve explains the age-dependent sensitivity (Faddy et al. 1992).  
The risk for ovarian failure depends also on the conditioning regimen used (Table 2). 
TBI is gonadotoxic and increases the risk of ovarian failure (Sanders et al. 1988). 
The fractionation of TBI reduces the risk of ovarian failure (Sanders et al. 1988). 
Busulfan as conditioning regimen associates with a high risk of ovarian failure and 
infertility (Borgmann-Staudt et al. 2012, Sanders et al. 1996, Bresters et al. 2014). 
Most of the females conditioned with TBI or busulfan will need hormonal 
replacement therapy for the induction of puberty and maintenance of menstrual 
cycles. Instead, the majority of girls conditioned with cyclophosphamide for SAA 
progress normally through puberty and experience menarche and have normal 
gonadotropins, have normal pregnancies and give birth to healthy offspring (Socie et 
al. 2003, Sanders et al. 1996, Sanders et al. 2011). This is contrary to the pregnancy 
rate among other female survivors, which is less than 2% (Socie et al. 2003).  
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Table 3. Evidence of Cardiovascular Late Effects after Cancer Treatment 
and/or HSCT in childhood. 
Author and 
Year 
Patients, 
n 
Follow-up 
time 
Cohort  Study Findings 
Alehan et al, 
2012 
72 9 years 
Pediatric HL, 
chemo and/or 
chest RT 
Mild systolic and diastolic 
dysfunction. 
Armstrong et 
al, 2013 
10,724 5 years CCS 
Cardiovascular risk factors 
potentiate cancer therapy-
associated risk for cardiac events. 
Bowers et al, 
2006 
37/63 5 years 
CCS, 
leukemia/brain 
tumors 
Increased risk to stroke after 
CRT >30 Gy. 
Brouwer et al, 
2013 
277 18 years 
CCS, 
anthracyclines 
and/or chest 
RT/TBI 
Increased carotid and femoral 
IMT associated to RT. 
Dengel et al, 
2014 
319 5 years CCS 
Increased carotid artery stiffness, 
premature atherosclerosis and 
cardiovascular disease. 
Gillis et al, 
2007 
31 5 years 
CCS, HR NBL, 
autoHSCT+ 
intraoperative 
RT 
Aortic stenosis, hypertension, 
vascular stenosis, renal artery 
stenosis, middle aortic syndrome. 
Kero et al, 2014 16,769 5 years CCS 
Cardiovascular diseases are 
second highest non-malignancy-
related causes of mortality. 
Küpeli et al, 
2010 
119 2 years CCS, HL 
Increased risk to coronary artery 
disease after >20 Gy chest RT. 
Meacham et al, 
2010 
8,599 >5 years 
CCS 
longitudinal 
study 
Older age, TBI/abdominal and 
chest RT are risk factors for 
hypertension, dyslipidemia, 
diabetes and microalbuminuria. 
Meeske et al, 
2009 
30 >10 years CCS, neck RT 
Increased carotid IMT and 
frequency of plaques. 
Taskinen et al, 
2000 
23 >10 years 
Pediatric 
alloHSCT 
Increased frequency of metabolic 
syndrome. 
Turanlahti et al, 
2012 
25 2 years 
Pediatric 
alloHSCT 
Early mechanical atherosclerotic 
changes of the arterial wall. 
Wilhelmsson et 
al, 2015 
204 >10 years 
Pediatric 
alloHSCT 
Cardiac late effect in 10% (mean 
age of 22 years). 
CCS, childhood cancer survivor; CRT, cranial radiotherapy; HL, Hodgkin lymphoma; HR NBL, 
high-risk neuroblastoma; HSCT, hematopoietic stem cell transplantation; IMT, intima-media 
thickness; RT, radiotherapy; TBI, total body irradiation 
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2.2.2.10 Cardiovascular and Metabolic Late Effects 
Cardiovascular diseases are emerging late effects after allogeneic HSCT in 
childhood, leading to considerable morbidity and mortality (Armenian & Bhatia 
2008) (Table 3). Irradiation and allogeneic HSCT, particularly if GVHD is present, 
have been shown to increase the risk for early vascular disease and poor cardiac 
function (Rovo et al. 2012). Cardiovascular diseases are in many cases related to 
extended atherosclerosis, contributed by cardiovascular risk factors in adult 
survivors(Tichelli et al. 2007, Tichelli et al. 2008, Armenian et al. 2010, Majhail et 
al. 2009, Griffith et al. 2010). The few reports from survivors transplanted in 
childhood show similar findings (Taskinen et al. 2000, Taskinen et al. 2007). 
Increased risk of classical metabolic syndrome, including dyslipidemia, central 
obesity, increased systolic blood pressure (BP), diabetes and physical inactivity, has 
been reported among pediatric long-term cancer or HSCT survivors (Heikens et al. 
2000, Meacham et al. 2010, Taskinen et al. 2000). Early mechanical changes have 
been described in carotid arterial wall after pediatric allogeneic HSCT (Turanlahti et 
al. 2013). Vascular complications including aortic and renal artery stenosis and 
middle aortic syndrome have been reported among HR NBL survivors (Gillis et al. 
2007). In a retrospective report of long-term health outcomes 10% of adult survivors 
after pediatric allogeneic HSCT had cardiac late effects and many suffered from 
metabolic disorders including diabetes type II (9%), dyslipidemia (7%), and 
hypertension (7%) (Wilhelmsson et al. 2015). Two of the survivors had died at a 
young adult age due to acute myocardial infarction and stroke. Both had received 
TBI-based conditioning (Wilhelmsson et al. 2015).  
Increased carotid artery intima-media thickness (IMT) (Bots et al. 1997) and 
systemic endothelial dysfunction detected by flow-mediated dilatation (FMD) are 
early signs of atherosclerosis (Neunteufl et al. 1997). Increased carotid artery IMT, 
endothelial dysfunction, increased arterial stiffness, decreased arterial compliance, 
and presence of arterial plaques predict subclinical cardiovascular disease (Neunteufl 
et al. 1997, Burke et al. 1995, O'Leary et al. 1999, Vlachopoulos et al. 2010).  
Radiation-related capillary endothelial injury associates with luminal obstruction, 
fibrin formation, and platelet thrombi leading to ischemia, myocardial cell apoptosis, 
and fibrosis (Adams & Lipshultz 2005). Radiation-induced subclinical 
atherosclerosis, carotid artery disease, carotid artery IMT thickening and arterial 
stenosis have been reported among adult cancer patients (Silverberg et al. 1978, 
Feehs et al. 1991, Dorresteijn et al. 2005, Shariat et al. 2008, Gianicolo et al. 2010, 
Carmody et al. 1999). Increased IMT and increased risk for stroke associate with RT 
(Dengel et al. 2014, Brouwer et al. 2013, Meeske et al. 2009, Bowers et al. 2006, 
Mueller et al. 2013, Bowers et al. 2005, Kupeli et al. 2010). The risk for stroke is 
increased with cranial radiotherapy (CRT) exceeding >30 Gy, and the risk for 
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coronary artery disease with chest RT doses >20 Gy (Bowers et al. 2006, Kupeli et 
al. 2010). Increased arterial stiffness, measured with aortic pulse wave velocity, has 
been reported among childhood cancer survivors after exposure to a mean dose of 
212 mg/m2 of anthracyclines without RT (Herceg-Cavrak et al. 2011). Another study 
could not confirm the independent effect of anthracyclines on arterial stiffness (King 
et al. 1999).  
The use of anthracyclines is known to be a primary contributor to cardiotoxicity 
resulting from direct cardiac myocyte apoptosis and leading to decreased 
contractility in the long term. The risk for heart failure is further increased if 
childhood cancer survivors have been exposed to chest irradiation, including TBI 
(Lipshultz et al. 2013). In international recommendations, survivors with cumulative 
anthracycline doses <100 mg/m2 are considered at low risk for cardiomyopathy and 
those with doses 100 to 250 mg/m2 or chest irradiation 15 Gy to 35 Gy at moderate 
risk (Armenian et al. 2015). The high-risk group consists of survivors with 
cumulative anthracycline doses >250 mg/m2 or chest irradiation >35 Gy or moderate 
doses of both (Armenian et al. 2015). However, there is some evidence that 
irradiation even with doses <15 Gy increases the risk of heart failure (Mulrooney et 
al. 2009, van der Pal et al. 2005, Armenian et al. 2011, Green et al. 2001).  
Cardiac dysfunction after childhood cancer treatment can develop after a long period 
of time. Usually diastolic dysfunction is seen first, followed by decreased systolic 
function. Early signs of cardiac dysfunction can be detected with three-dimensional 
echocardiography (3DE) and Tissue Doppler Imaging (TDI) (Alehan et al. 2012, 
Armstrong et al. 2015). Left ventricular mass (LVM) predicts cardiovascular 
morbidity in general population and emphasizes the importance of estimation of 
LVM also among childhood cancer survivors (Hunt et al. 2009, Levy et al. 1990). 
Hypertension is known to independently potentiate the risk for cardiac failure 
(Armstrong et al. 2013). Classic cardiovascular risk factors further increase LVM 
and the risk of heart failure (Berry et al. 2012) (Figure 3).  
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Figure 3. Premature atherosclerotic process described in hypothetical diagram in 
long-term survivors after childhood hematopoietic stem cell 
transplantation (HSCT). Pre-HSCT exposure, possible previous cancer therapy; 
HDTx, high dose therapy; GVHD, graft-versus-host disease. 
2.2.2.11 Neuropsychological Late Effects 
Fatigue and sleeping disorders have been reported among 65% of adult patients after 
HSCT (McQuellon et al. 1998). Problems with short-term memory and mild 
cognitive impairments have been described in approximately 10% to 20% of patients 
within the first year after HSCT (Meyers et al. 1994). Lower intelligence quotient 
(IQ) levels have been identified especially among pediatric patients transplanted at a 
very young age, but the changes were minimal and remained stable at the 3-year 
follow-up (Kramer et al. 1992, Phipps et al. 2000). 
2.2.2.12 Secondary Malignancy 
Factors that contribute to the development of secondary malignancies after HSCT 
include cytotoxic and immunosuppressive therapy, GVHD or antigenic stimulation, 
viruses, immunodeficiency, and genetic predisposition. Incidence of secondary 
malignancy of 2.6% to 9.9% has been reported after childhood HSCT (Wilhelmsson 
et al. 2015, Bhatia et al. 1996, Danner-Koptik et al. 2013). The most common 
secondary malignancies after HSCT are posttransplant lymphoproliferative disorders 
(PTLD), hematologic malignancies (AML, MDS), and solid tumors (carcinomas,
sarcomas, CNS tumors) (Deeg & Socie 1998). 
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2.2.2.13 Late Effects Associated with Conventional Chemotherapy prior 
to HSCT 
The role of HSCT in treatment of childhood cancer is to consolidate the remission. 
Remission can be induced by conventional chemotherapy, RT and molecularly 
targeted agents, usually in combinations (Table 4). This conventional therapy 
modifies the late effects after HSCT. 
Children with a history of CRT are at a higher risk of cognitive deficits after HSCT 
(Socie et al. 2003). Anthracyclines, such as doxorubicin, are widely used in many 
malignant diseases. Anthracyclines have selective toxicity to cardiomyocytes and 
there is a limiting cumulative dose that should not be exceeded. Asparaginases, used 
to treat ALL and lymphoma, cause pancreatitis, coagulopathy and thrombosis. 
Methotrexate, used to treat leukemias, lymphomas, and osteosarcomas, can cause 
renal and tubular dysfunction. Cisplatin, used to treat testicular tumors, brain tumors, 
osteosarcomas, and NBLs, can lead to permanent renal- and ototoxicity. 
Cyclophosphamide and ifosfamide, used to treat leukemias, lymphomas, NBLs, 
sarcomas and germ cell tumors, are nephrotoxic and increase the risk of infertility. 
Vincristine, used to treat ALLs, lymphomas, and solid tumors, is neurotoxic and can 
cause persisting peripheral neuropathy with walking difficulties. 
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Table 4. Chemotherapy Agents Used in Pediatric Oncology. 
Alkylating Agents 
Cyclophosphamide, Ifosfamide, 
Mechlorethamine, Melphalan, Busulfan, 
Thiotepa, Chlorambucil, Bendamustine 
Nitrosoureas: Carmustine, Lomustine 
Not classical alkylating agents: Dacarbazine, 
Procarbatzine, Temozolomide 
Antimetabolites 
Cytarabine, Azacytidine, Decitabine, 
Gemcitabine, Cladribine, Clofarabine, 
Fludarabine, Nelarabine, 6-Mercaptopurine, 6-
Thioguanine, Hydroxyurea, 5-Fluorouracil, 
Capecitabine, Methotrexate, Pemetrexed 
Antitumor Antibiotics 
Anthracyclines: Doxorubicin, Epirubicin, 
Daunorubicin, Idarubicin 
Bleomycin, Dactinomycin, Mitomycin C, 
Mitoxantrone 
Asparaginases l-Asparaginase, Crisantaspase, Pegasparaginase 
Corticosteroids Dexamethasone, Prednisolone, Prednisone 
Platinum Compounds Carboplatin, Cisplatin, Oxaliplatin 
Retinoids All-trans-retinoic acid, 13-cis-retinoic acid 
Topoisomerase-Interactive Agents Etoposide, Teniposide, Irinotecan, Topotecan 
Tubulin-Interactive Agents 
Docetaxel, Paclitaxel, Vinblastine, Vincristine, 
Vinorelbine 
Tyrosine Kinase Inhibitors 
Imatinib, Dasatinib, Nilotinib, Ponatinib, 
Sunitinib, Sorafenib, Erlotinib, Gefitinib, 
Crizotinib, Pazopanib, Vemurafenib 
Proteasome Inhibitors Bortezomib 
Histone Deacetylase Inhibitors 
Vorinostat, Arsenic trioxide, Everolimus, 
Temsirolimus, Ruxolitinib, Vismodegib 
Antibodies 
Rituximab, Gemtuzumab ozogamicin, 
Brentuximab vedotin, Alemtuzumab, 
Bevacizumab 
Biological Response Modulator Aldesleukin 
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2.3 Accelerated Aging 
2.3.1 Aging 
In the normal aging process, physiological changes occur in all organ systems. The 
cardiac output decreases linearly after 30 years of age, blood pressure elevates 
physiologically progressively after 10 years of age, and atherosclerosis clearly 
increases with aging. The respiratory system shows impaired gas exchange, a linear 
decrease in vital capacity with an increase in residual volume, and slower expiratory 
flow rates. The glomerular filtration rate decreases and a progressive elevation of 
blood glucose occurs on a multifactorial basis. Menopause is a sign of ovarian aging 
that typically occurs between 45 and 55 years of age. Peak bone mass is attained at 
20 years of age, decreasesing physiologically thereafter (Boot et al. 2010). 
Osteoporosis is frequently seen after 40 years of age due to a linear decline in bone 
mass. Atrophy of the epidermis, stiffer dermal collagen, calcification of elastin and a 
decrease in the number of dermal blood vessels cause the skin to lose its tone and 
elasticity. Loss and atrophy of muscle cells lead to decreased lean body mass. 
Degenerative changes occur in many joints; this, combined with the loss of muscle 
mass, leads to limitations in physical activity (Boss & Seegmiller 1981).  
Early appearance of the signs of aging is called premature aging. The aging process 
is accelerated by acute insult, such as illness, injury or major life events, affecting 
organs or producing inactivity. Suboptimal lifestyle choices, such as inactivity, 
smoking, and a diet high in fat and sugar, increase the risk of high BP and contribute 
to the early structural changes of the arterial wall. This leads to the stiffening of large 
elastic arteries and causes early vascular aging (Vatanen et al. 2015). Exposures to 
DNA damaging agents and genetic diseases affecting genomic stability have evolved 
as other causative factors for premature aging (Shay & Wright 2007). 
2.3.2 Biomarkers of Aging 
Telomeres are repetitive DNA sequences at the ends of chromosomes that are 
involved in the maintenance of genomic stability and DNA repair. The end-
replication problem causes some telomere sequences to be lost each time a cell 
divides and chromosomes replicate. At some point, when cells reach maximally 
shortened telomere length, they enter a replicative senescence state. Tissue 
regeneration is reduced and this leads to tissue dysfunction and chronic conditions 
that are often associated with increased age such as diabetes, cancer, and 
cardiovascular disease (Shay & Wright 2007). Consequently, telomere shortening 
serves as a biomarker of cellular senescence and aging.  
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Dyslipidemia, inflammation, increased body mass index (BMI), hypertension, 
diabetes, smoking, heavy alcohol intake and physical inactivity have been associated 
with shortened telomeres (Weischer et al. 2012, Butt et al. 2010, Cherkas et al. 2008, 
Shay & Wright 2007). Abnormal telomere shortening has been reported in Wilms’ 
tumor tissues (Stewenius et al. 2007) and buccal cell DNA samples among childhood 
cancer survivors who develop second malignant neoplasms (Gramatges et al. 2014). 
On the other hand, there is some evidence that after bariatric surgery, weight loss can 
increase telomere length in a 10-year follow-up (Laimer et al. 2015).  
Other biomarkers of cellular senescence include sterile proinflammatory state or 
senescence-associated secretory phenotype, resulting in elevated levels of 
inflammatory markers, including C-reactive protein (CRP), interleukin-6, tumor 
necrosis factor (TNF), and immune cell cytokines (Tchkonia et al. 2013). It is 
believed that this chronic inflammation may further contribute to the development 
and progression of chronic conditions such as insulin resistance, diabetes, 
hypertension, atherosclerosis and cardiovascular disease (Cesari et al. 2003, Ness et 
al. 2015). 
2.3.3 Frailty 
Decreased well-being and increased levels of frailty often accompany advanced age. 
Although chronological and biological age correlate, individuals with the same 
chronological age may vary widely in terms of health and functional status. The 
concept of frailty attempts to explain this heterogeneity. There is a growing 
consensus that markers of frailty include age-associated declines in lean body mass, 
strength, endurance, balance, walking performance, and low activity (Ness et al. 
2015). The Canadian Study of Health and Aging has approached frailty with a frailty 
index, measured with symptoms, signs, diseases, and disabilities as deficits up to 70 
items, and an index score indicates the likelihood that frailty is present (Rockwood 
& Mitnitski 2007). Fried et al, have provided a standardized definition for frailty, 
and they have created the concept of frailty phenotype that identifies old people who 
are at risk of disability, falls, institutionalization, hospitalization, and premature 
death (Fried et al. 2001).  
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According to this concept, a person is prefrail if two and frail if three or more of the 
following criteria are fulfilled: 
1) Loss of muscle mass defined by lean muscle mass below -1.5 standard deviations 
(SD), measured with dual-energy X-ray absorptiometry dividing by height in meters 
squared (Ness et al. 2013, Kelly et al. 2009).  
2) Weakness defined by using different strength tests like grip strength or sit-up test 
(Fried et al. 2001, Ness et al. 2013).  
3) Self-reported exhaustion defined by special questionnaires (Ness et al. 2013, Fried 
et al. 2001).  
4) Slowness defined by walking or running speed below lowest 20th percentile or 
less than -1.5 SD for age, sex and height values (Fried et al. 2001).  
5) Low energy expenditure defined by weekly physical activity level among men 
with less than 383 kcal/wk and women with less than 270 kcal/wk when measured 
by questionnaire and converted to kilocalories per week.  
Chronic disease can advance functional decline and frailty. Increased frequency of 
frailty phenotypes have been reported among adult childhood cancer survivors (Ness 
et al. 2013) and patients with chronic kidney disease (Musso et al. 2015). In the St 
Jude Lifetime cohort, the combined prevalence of frailty and prefrailty among 
childhood cancer survivors was 41% among CNS tumor, 39% among soft tissue 
sarcoma, 39% among other solid tumor and 30% among leukemia, lymphoma and 
bone tumor survivors (Ness et al. 2013). In the same study, 13% of control women 
and 3% of control men at the mean age of 33 years were considered frail and 32% of 
women and 13% of men prefrail (Ness et al. 2013). A prevalence of frailty 
phenotype of 11% is reported in a meta-analysis of community-dwelling persons at 
least 65 years old and 26% among persons older than 85 years (Collard et al. 2012). 
The prevalence of frailty that is similar to ≥65 years old in the control population 
suggests significantly accelerated aging among young adult survivors of childhood 
cancer. 
Young adult survivors of childhood cancer report several symptoms that interfere 
with daily life, including exercise-induced shortness of breath (Mertens et al. 2002), 
fatigue (Johannsdottir et al. 2012), and reduced capacity to participate in physical 
activity (Jarvela et al. 2010). These symptoms may also be indicators of premature 
aging or frailty (Table 5). 
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Table 5. Evidence of Frailty Phenotype among Childhood Cancer Survivors. 
Author and Year Patients, n 
Follow-up 
time 
Cohort Study Findings 
Chemaitilly et al, 
2015 
748 >15 years 
CCS with 
previous CRT 
Anterior pituitary deficits 
GHD 46.5%, LH/FSHD 
10.8%. 
Järvelä et al, 2010 21 16 years ALL 
Poor physical activity 
index 30%/36% (M/F). 
Jóhannsdóttir et 
al, 2012 
584 4-20 years CCS Chronic fatigue 14%. 
Mertens et al, 
2002 
12,390 >5 years CCS 
Exercise-induced 
shortness of breath, RR 
3.0. 
Ness et al, 2013 1,922 >10 years CCS 
Prevalence of pre-frail/ 
frail phenotype 
31.5%/13.1% vs. 
12.9%/2.7% (F/M). 
Oeffinger et al, 
2006 
10,397 18 years CCS 
Chronic health conditions 
cumulative incidence 
73.4%. 
Wilhelmsson et al, 
2015 
204 >10 years 
Pediatric 
alloHSCT 
At least one chronic health 
condition 84%, at least one 
grade 3 condition 41%. 
Zhang et al, 2015 22 6 years CCS 
Poor Healthy Eating Index 
Score 52.7/100. 
ALL, survivors of acute lymphoblastic leukemia; alloHSCT, allogeneic hematopoietic stem cell 
transplantation; CCS, childhood cancer survivors; CRT, cranial radiotherapy; F, female; FSHD, 
follicle stimulating hormone deficiency; GHD, growth hormone deficiency; LHD, luteinizing 
hormone deficiency; M, male; RR, relative risk 
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3 Aims of the Study  
The goal of this thesis was to examine ovarian function, cardiovascular health, 
fitness, muscle mass, and physical activity in adult and adolescent survivors after 
HSCT in childhood. The hypothesis of this study was that a declined function in 
these aging-associated measures is detected among HSCT survivors but not among 
the age-matched controls. 
The specific aims of the present study were: 
1. To evaluate long-term ovarian function after allogeneic HSCT in childhood 
and adolescence with retrospective case note review. 
2. To investigate cardiovascular risk factors, central and peripheral arterial 
morphology, arterial stiffness, and endothelial function in young adult 
survivors of HR NBL compared to healthy age- and sex-matched controls.  
3. To investigate left ventricular mass and function in conjunction with a 
comprehensive cardiovascular risk assessment in young adult survivors of 
HR NBL compared to healthy age- and sex-matched controls.  
4. To estimate the prevalence of frailty and its association with cardiovascular 
health, inflammation, and telomere length in young adult survivors of HR 
NBL and age- and sex-matched controls.   
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4 Patients and Methods  
4.1 Patients 
4.1.1 Female Long-Term Survivors after Allogeneic HSCT in Childhood 
(I) 
Female long-term survivors who were less than 20 years of age when receiving 
allogeneic HSCT at the Children’s Hospital, Helsinki University Hospital, Helsinki, 
Finland, or Karolinska University Hospital Huddinge, Stockholm, Sweden, between 
1978 and 2000, were identified through hospital records and enrolled in the study 
assessing long-term health outcome after childhood HSCT (Figure 4). 
 
 
 
 
 
 
 
 
 
 
Figure 4. Patient selection process in Helsinki-Huddinge retrospective study. 
HSCT, hematopoietic stem cell transplantation. 
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4.1.1.1 Treatment Characteristics 
Leukemia patients were treated according to the Nordic protocols for ALL (since 
1982) and AML (since 1984) (Gustafsson et al. 2000, Lie et al. 2005). Conditioning 
treatments were changed over time and protocols differed between Helsinki and 
Huddinge (Table 6).  
During the years 1978-1995, leukemia patients at the Karolinska University Hospital 
Huddinge, received cyclophosphamide (120mg/kg) combined with sTBI 10 Gy as 
the standard conditioning. In 1993 fTBI 12 Gy was introduced. Since 1996, the 
patients transplanted with AML have been conditioned with cyclophosphamide 
(120mg/kg) combined with busulfan (16mg/kg). Patients with SAA were 
conditioned with cyclophosphamide (200mg/kg). Patients with congenital metabolic 
defects were conditioned with busulfan (16mg/kg), usually with cyclophosphamide 
(200mg/kg).  
During the years 1978-1983, patients treated at the Helsinki University Hospital 
received sTBI 10-12 Gy. Since 1984 patients have received fTBI 10-12 Gy together 
with cyclophosphamide (120mg/kg), cytarabine (36mg/m2), melphalan (210mg/m2) 
or busulfan (16mg/kg). Patients with SAA were conditioned with cyclophosphamide 
(200mg/kg) with or without fTBI 10 Gy or total lymph node irradiation (TNI) 6 Gy. 
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Table 6. Patient characteristics of female long-term survivors after pediatric 
HSCT. 
Characteristics 
Study patients n=92 
n (%) 
Diagnosis group 
ALL 33 (36) 
AML 24 (26) 
SAA 13 (14) 
Others 22 (24) 
CRT for leukemia 
No 45 
Yes 12 
Remission status of leukemia 
CR 1 28 
CR 2-4 29 
Conditioning 
sTBI+Cy 29 (32) 
fTBI+Cy 22 (24) 
fTBI+Cy+ETO 1 (1) 
fTBI+cytarabine 16 (17) 
fTBI+melphalan 3 (3) 
Bu 2 (2) 
Bu+Cy 8 (9) 
Cy only 10 (11) 
Cy+TNI  1 (1) 
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Bu, busulfan; CR, complete 
remission; CRT, cranial radiotherapy; Cy, cyclophosphamide; ETO, etoposide; fTBI, fractioned total 
body irradiation; HSCT, hematopoietic stem cell transplantation; SAA, severe aplastic anemia; sTBI, 
single fraction total body irradiation; TBI, total body irradiation; TNI, total nodal irradiation 
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4.1.2 Long-Term Survivors of HR NBL and Healthy Controls (II-IV) 
A national cohort of long-term HR NBL survivors was enrolled in this follow-up 
study (Figure 5). One patient with high-risk retinoblastoma treated in accordance 
with the HR NBL protocol was also included. All patients over 16 years of age at the 
time of the study were included. The patients were born in 1996 or earlier and were 
treated at any of the five University Hospitals in Finland between 1980 and 2000.  
 
Figure 5. Study recruitment process in high-risk neuroblastoma (HR NBL) clinical 
study. HR, high-risk. 
Twenty healthy individually age- and sex-matched controls were recruited as 
controls among medical students and teenage children of hospital employees. 
4.1.2.1 Treatment Characteristics 
HR NBL diagnosis was based on the INSS classification system (Brodeur et al. 
1993, Brodeur et al. 1988) and was also in accordance with the newer INRG system 
(Cohn et al. 2009) (Table 1). Conventional chemotherapy included combinations of 
cyclophosphamide, dacarbazine, vincristine, etoposide, cisplatin, doxorubicin, 
ifosfamide, or carboplatin and was administered to make the primary operation 
easier, to eradicate metastatic disease, and to clean bone marrow to obtain an 
autologous stem cell graft (Saarinen-Pihkala et al. 2012, Saarinen et al. 1996). The 
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mean cumulative doxorubicin exposure was 88 mg/m2 (range 0-210) and the mean 
cumulative cisplatin exposure 387 mg/m2 (range 180-820).  
All patients were consolidated with HDTx and autologous HSCT. Patients with bone 
metastases, MYCN amplification and poor treatment responses were stratified into 
fTBI-based HDTx 10-12 Gy. Single HDTx included PEM-TBI (cisplatin, etoposide 
and melphalan, and TBI of 10-12 Gy in five to six fractions), CEM-TBI (carboplatin, 
etoposide and melphalan, and TBI of 10 Gy in five fractions), L-PAM (melphalan) 
or ETO/Topo-Carbo-TT (etoposide or topotecan, carboplatin and thiotepa) 
(Saarinen-Pihkala et al. 2012). Two patients received tandem HDTx and both were 
consolidated with L-PAM in the first HDTx; in the second HDTx one received ETO-
Carbo-TT without TBI and the other with TBI of 10 Gy (Saarinen-Pihkala et al. 
2012).  
After recovery, local RT was administered to the primary and bulky metastatic sites 
to all but one survivor and consisted of orbital area with 20 Gy, mandibular area with 
32 Gy, occipital area with 20 Gy, left lung with 12.6 Gy, left kidney, lumbosacral 
area with 18 Gy, mediastinum and clavicular area with 24 Gy, abdomen with 7.2 Gy 
or retroperitoneal area with 12.6-45 Gy (Saarinen-Pihkala et al. 2012).  
4.2 Methods 
4.2.1 Analysis of Ovarian Function in the Retrospective Study (I) 
The follow-up data were collected from medical records by one PhD student (V.A.) 
in Finland and one (W.M.) in Sweden. The follow-up time comprised the time from 
HSCT to the latest documented follow-up visit. Occurrence of spontaneous puberty 
based on breast development, age at menarche, the use of estrogen substitution for 
non-contraceptive reasons, and pregnancies were collected from the follow-up 
records if available. Information about pubertal or postpubertal serum follicle 
stimulating hormone (FSH) levels prior to initiating the estrogen substitution, or any 
postpubertal value for those without estrogen substitution, were collected.  
Serum FSH values 1-12 IU/L were considered within the normal reference range and 
serum values >25 IU/L at menopausal level. Premature menopause was documented 
by increased levels of FSH and failure to accomplish pubertal maturation or 
menstruation among girls who showed some ovarian activity after HSCT. Increased 
levels of FSH documented ovarian failure with no ovarian activity after HSCT. 
4.2.2 Clinical Examination (II-IV) 
The recruitment letter was sent to all HR NBL survivors in Finland. The age-
matched controls were contacted personally. After consenting, the study participants 
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were invited to fill in a questionnaire, and clinical examinations including interview 
were performed during the winter 2011-2012. Clinical data on the cancer treatment 
and medical history were collected from the medical records. Cumulative doses of 
anthracycline and cisplatin were calculated from medical records. If cumulative 
doses were not found, estimated doses from the treatment protocol were used. 
Height and weight were measured and BMI [weight (kg)/height (m)2] and body 
surface area (BSA) (m2) from Mostellers’ formula [square root of height 
(cm)*weight (kg)/3600] were calculated. Very high frequency ultrasound of the 
arteries, 3DE and TDI ultrasounds, FMD test, 24-hour ambulatory blood pressure 
measurement (ABPM), body composition measured with dual-energy X-ray 
absorptiometry, and physical performance tests were performed. A detailed history 
of health, smoking and physical activity limitations, and ongoing endocrine 
replacement therapies and anti-hypertensive medications were assessed by a 
questionnaire. Clinical examination day was planned and organized by a PhD 
student (V.A.). 
4.2.2.1 Biochemistry (II-IV) 
Laboratory analyses were determined from venous blood samples taken in the 
morning of the examination day following overnight fasting (minimum 11 hours), 
using standard techniques in the laboratory of Helsinki University Central Hospital. 
Glucose and lipid metabolism analyses were performed using standardized methods 
for blood glucose, glycosylated hemoglobin A1c (GHbA1c), total cholesterol, high- 
and low-density lipoproteins (HDL, LDL) and triglycerides. Cardiac biomarker N-
terminal pro-B-type Natriuretic Peptide (pro-BNP), inflammation markers high-
sensitivity C-reactive protein (hsCRP) and TNF-alpha, insulin-like growth factor 1 
(IGF-1), renal function parameters cystatin C, uric acid and urine albumin/creatinine 
ratio were assessed using standardized methods in Studies II-IV. 
4.2.2.2 Ambulatory Blood Pressure (II-IV) 
Right arm systolic and diastolic BPs were measured during imaging ultrasound 
examinations in the supine position at rest with appropriate-sized cuffs with the GE 
Carescape Dinamap V100 device and the average of three BP measurements was 
used in vascular calculations.  
ABPM was performed with an automated monitor (Schiller BR-102 Plus, Schiller 
AG, Baar, Switzerland) using oscillometric measurement as backup to ensure the 
accuracy of auscultator measurement results. ABPMs were obtained for at least 20 
hours. The ABPM device was programmed to measure BP every 30 minutes 
between 7 am and 10 pm and hourly thereafter until 7 am the following morning. 
4 Patients and Methods 
40 
The subjects kept a diary based on which daytime and nighttime periods were 
defined, as well as what kind of activity occurred, for example doing sports, 
watching a horror movie, walking or anything which can affect BP. Twenty-four-
hour mean total, daytime and nighttime systolic and diastolic BPs, mean heart rate 
and the proportions of systolic and diastolic measurements exceeding limits were 
assessed in accordance with the European recommendations (Lurbe et al. 2009, 
O'Brien et al. 1991). BP load was calculated by dividing the count of measurements 
exceeding the 95th percentile cut-off values by the count of measurements during the 
study period. Nocturnal dipping was denoted as the difference between average 
daytime and nighttime BPs. 
4.2.3 Arterial Morphology and Stiffness (II) 
4.2.3.1 Arterial Morphology 
B-mode ultrasound recordings of bilateral common carotid, brachial, radial and 
femoral arteries were obtained with very-high-resolution ultrasound (VHRU) using 
the Vevo 770 ultrasound system (Visualsonics, Toronto, Canada) with mechanical 
25 MHz (RMV710B), 35MHz (RMV712) and 55 MHz (RMV708) transducers. The 
highest ultrasound frequency able to image the vessel was used with 55 MHz applied 
for the radial and 25/35 MHz for the brachial, femoral and common carotid arteries. 
All images were obtained and measurements made later offline by one senior 
pediatric cardiologist (S.T.) blinded to the study group and clinical characteristics. 
The mean of three electronic caliper measurements per artery was calculated and the 
mean of right and left assessments was used in the final analyses as no differences 
between right and left were observed. IMT from the carotid artery, and IMT and 
intima-media-adventitia thicknesses (IMAT) from all other arteries were measured 
together with the lumen diameter (LD) at end-diastole (Figure 6). A double line 
appearance in the proximity of the lumen-intima interface was observed when 
imaging the radial artery with 55 MHz (assessed in all subjects) and in the common 
femoral artery using 35 MHz (not accessible in all subjects) and was interpreted as a 
thickened intima layer. 
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Figure 6. Image of the radial artery obtained with 55 MHz in a HR NBL patient. 
The arrows mark the leading edges of the dimensions measured. LD, 
lumen dimension; IMT, intima-media thickness. 
All arterial sites were screened for the presence of arterial plaques (Figure 7). The 
presence of a local arterial plaque was defined as a structure that encroaches into the 
arterial lumen at least 0.5 mm or 50% of the surrounding IMT or demonstrates an 
IMT of 1.5 mm or more (Touboul et al. 2012). 
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Figure 7. Image of the carotid artery obtained with 12 MHz in a total body 
irradiation treated high-risk neuroblastoma survivor, displaying plaques 
encroaching into vessel lumen from the near and far walls of the artery at 
the bifurcation of the common carotid artery and extending distally to the 
carotid bulb. 
4.2.3.2 Arterial Stiffness 
Common carotid peak-systolic and end-diastolic LDs were measured with 25 MHz 
with simultaneously obtained electrocardiogram (ECG) and the average of three 
ultrasound measurements was used in vascular stiffness calculations. Stiffness index 
was calculated from carotid measures as Ln (systolic BP/diastolic BP)/[(peak-
systolic LD- end-diastolic LD)/end-diastolic LD)]. Carotid compliance was 
calculated from carotid measures as [(peak-systolic LD- end-diastolic LD)/end-
diastolic LD]/(systolic BP- diastolic BP).  
4.2.3.3 Flow-Mediated-Dilatation 
Brachial artery FMD ultrasound studies were performed by an operator experienced 
in this technique (O.T.H.) with Vivid 7 ultrasound (Vivid 7; GE Vingmed AS) using 
the 12L vascular probe (GE Medical Systems). Patients were examined after 20 min 
of rest in a quiet, temperature-controlled and darkened room. Right brachial artery 
diameter was tracked using semi-automatic border detection software both at rest 
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and during reactive hyperemia induced by inflation of a pneumatic tourniquet placed 
around the forearm to a pressure of 300 mmHg for four minutes (Figure 8), as 
previously done with children (Tounian et al. 2001, Aggoun et al. 2004). Repeat 
ultrasound records of the brachial artery were obtained at a fixed distance from an 
anatomic marker at rest and continuously 30 to 210 seconds after cuff release.  
 
 
Figure 8. Flow-mediated dilatation analysis in a high-risk neuroblastoma survivor. 
Lumen diameter (LD) tracked using semi-automatic border detection 
software from brachialis artery.
All ultrasound scans were analyzed offline by the same observer (V.A.) blinded to 
the subjects’ details. Datasets were analyzed with a semi-automatic image analysis 
software package (AMS II, version 1.1331, Chalmers University of Technology, 
Gothenburg, Sweden). The recognition of each diameter measurement was based on 
the direction and timing of the electrocardiography wave at end-diastole. The mean 
values of base and FMD diameters were calculated from three measurements. 
 
FMD%= BAD hyperemia- BAD at rest X100 BAD at rest 
 
Abbreviations: BAD= brachial artery diameter; FMD= flow-mediated-dilatation 
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4.2.4 Three-Dimensional Echocardiography and Tissue Doppler 
Imaging (III) 
LVM and left ventricular (LV) function were examined in the morning prior to blood 
sampling. One senior pediatric cardiologist (O.T.H) performed cardiac imaging and 
3DE analyses from standard views in accordance with the American Society of 
Echocardiography and the European Association of Cardiovascular Imaging Expert 
Consensus (Plana et al. 2014). TDI analyses of systolic and diastolic functions were 
performed retrospectively by one observer (V.A.). 
4.2.4.1 Assessment of 3DE Left Ventricular Volumes and Mass  
All studies were performed using the Philips IE33 ultrasound system (Philips, 
Andover, MA, USA) with an X5-1 matrix-array transducer. 3DE datasets were 
analyzed using commercial software (Qlab v8, Philips Medical Systems, Andover, 
MA, USA). The 3DE LVM was calculated at both end-diastole and end-systole. 3DE 
measurements were made by subtracting the endocardial volume from the epicardial 
volume and multiplying by 1.05 to correct for the density of cardiac muscle (Figure 
9). As the agreement between systolic and diastolic LVM was good, the repeatable 
systolic LVM was selected as a final outcome variable (Ojala et al. 2015). LVM was 
normalized to height (in meters) to the power of 2.7 (LVM index, LVMI) and 
expressed as g/m2.7 (de Simone et al. 1992). Survivors’ LVMI was compared to the 
study controls, and values exceeding 2SDs were consider as LV hypertrophy.  
 45 
 
Figure 9. The 3DE left ventricular mass measurements performed by subtracting 
the endocardial volume from the epicardial volume at both end-diastole 
and end-systole. 3DE end-systolic (ESV) and end-diastolic volumes 
(EDV), systolic function with ejection fraction (EF), and 16-segment 
synchrony dataset analyses in a high-risk neuroblastoma survivor. 
4.2.4.2 Assessment of Cardiac Function and Dyssynchrony 
Ejection fraction (EF), stroke volume and 16-segment dyssynchrony index (16 SDI) 
were calculated according to standard formulas from the 3DE endocardial datasets of 
LV volumes at end-diastole and end-systole (Figure 9). TDI was performed from the 
apical four-chamber view with Pulse Wave Doppler (PW). The peak systolic (TDI 
S’) and early diastolic (TDI E’) tissue velocities were measured as a mean of three 
cardiac cycles directly on the spectral display (Figure 10). The recognition of each 
peak velocity was based on the direction and timing of the wave on ECG. Systolic 
functional evaluation was based on 3DE EF, 3DE stroke volume (SV) and TDI S’ 
(Plana et al. 2014). The early LV inflow diastolic velocity (PW E) was measured 
with PW (Figure 10). The calculation of E/E’ was used as an estimation of cardiac 
diastolic function (Plana et al. 2014).  
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Figure 10. Example of analysis of peak velocities measured by Tissue Doppler 
Imaging (TDI) in a high-risk neuroblastoma survivor. The peak systolic 
(TDI S’) and diastolic (TDI E’) velocities are indicated. The early left 
ventricular inflow diastolic velocity (PW E) was measured with Pulse 
Wave Doppler (PW). 
4.2.5 Tests for Physical Performance (III-IV) 
Muscular endurance, strength and speed were investigated by different tests: leg-lift, 
repeated squatting, sit-up, back extension and shuttle-run. One physiotherapist 
(K.M.) performed the tests. Age- and sex-spesific control values from our previous 
study were used (Hovi et al. 2010). A designated personal muscle sum score was 
determined by calculating the mean SDS value for the five muscle tests. The SDS 
values of patients were used in the analyses. In addition, the study subjects were 
interviewed and a detailed history of activity levels was recorded in accordance with 
the National Health and Nutrition Examination Study. 
 
 
Figure 11. Physical performance tests. 
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The tests used, described more precisely in our previous report (Hovi et al. 2010), 
are described briefly below (Figure 11): 
1. Leg-Lift Test: This test measures the speed endurance of lower extremities, 
especially the hip flexors. The subject stands in front of a bench and is asked to lift 
both feet alternately onto the bench as quickly as possible for 30 seconds. 
2. Repeated Squatting Test: This test measures the dynamic endurance of lower 
extremities. The subject is asked to squat and stand up as many times as possible for 
30 seconds. 
3. Sit-Up Test: This test measures the dynamic muscular endurance of the trunk 
flexors. The subject, lying supine with the knees flexed and ankles supported, is 
asked to rise to a sitting position as many times as possible for 30 seconds. 
4. Back-Extension Test: This test measures the dynamic endurance of the trunk 
extensors. The subject lies prone on a bench with the ankles supported and the trunk 
from the sacral spine upward unsupported when in the horizontal position and is 
asked to lower and lift the trunk as many times as possible for 30 seconds. 
5. Shuttle-Run Test: The test measures acceleration, maximal speed, and speed 
differentiation. The subject makes a 10 x 5 m shuttle run as fast as possible. 
4.2.6 Frailty Phenotype and Telomere Length Analysis (IV) 
Participants were defined as pre-frail if they fulfilled two and frail if they fulfilled 
three or more of the following criteria as originally defined by Fried et al. (Fried et 
al. 2001) (Table 7). 
 
Table 7. Frailty phenotype. 
Characteristics of Frailty Outcome 
Low lean muscle mass <-1.5SD lean mass (kg)/ height (m2) 
Low energy expenditure Men <383 kcal/wk, Women <270 kcal/wk 
Slowness Shuttle run test <-1.5SD 
Weakness Sit up test <-1.5SD 
Exhaustion Not assessed in this study 
SD, standard deviations 
 
Body composition, as total body and trunk fat mass (kg), and total body lean mass 
(kg) and total body and trunk fat percentage, were measured with dual-energy X-ray 
absorptiometry (DXA; Hologic® Discovery A, Bedford, MA, software version 
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12.3:3). Low lean muscle mass was classified as less than -1.5SD for race-, age- and 
sex-specific values from the National Health and Nutrition Examination Study 
(Kelly et al. 2009). In accordance with the National Health and Nutrition 
Examination Study, detailed information of activities from physical performance 
interview was converted to kilocalories per week (kcal/wk) (Centers for Disease 
Control and Prevention: National Health and Nutrition Examination Survey 
Physical Activity and Physical Fitness: PAQ 2007). Shuttle-run and sit-up test 
results were evaluated as SD values comparing to the age- and sex-specific values 
from our previous study (Hovi et al. 2010). 
4.2.6.1 Telomere Length Analysis 
Frozen blood samples, which were collected in the morning of the examination day, 
were used for telomere length analysis in Karolinska Institute, Sweden, by two 
experienced operators (H.M. and H.T.). Genomic DNA was isolated using 
phenol/chloroform and telomere length was assessed by real-time PCR as described 
(Cawthon 2002). 
4.2.7 Statistical Methods 
Data are presented as mean±SD (range). Mann-Whitney U test (for continuous 
variables), Fisher’s exact test and χ2 test (for categorical variables) were conducted 
to test differences between two groups. Association between variables was analyzed 
with Spearman’s correlation. 
In Study I, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated 
using bi- and multivariate logistic regression analyses. Categorical predictors used in 
logistic bi- and multivariate regression analysis were the dummy variables (0/1) 
prepubertal at HSCT, leukemia diagnosis, SAA diagnosis, TBI and sTBI or fTBI. 
The continuous variables were age at HSCT, follow-up time, serum level of FSH, 
and for the leukemia group only, remission status at HSCT and CRT. 
In Study II, simple and multiple linear regression analyses were used to study 
associations with vascular parameters and cardiovascular risk factors, treatments and 
BSA between survivors and controls or TBI- and non-TBI survivors. Age and gender 
were not adjusted for, due to matching survivor and control groups.  
In Study III, LVMI and LVMI/end-systolic volume (ESV) were used in simple and 
multiple linear regression analyses as dependent variables and survivor/control, 
triglycerides and mean 24-hour systolic BP (24SYS) as independent variables.  
In Study IV, all data are presented as median/mean±SD (range). The phenotypes of 
frailty, pre-frailty and non-frailty were the primary outcomes. The parameters that 
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correlated significantly with telomere length were further added to simple and 
multiple linear regression analysis; as independent variables we used GHbA1c, 
hsCRP, and IGF-1. 
A p-value of <0.05 was considered statistically significant. Analyses were performed 
using the IBM SPSS statistical software package (version 22). All statistical analyses 
in Studies II-IV were made by V.A. and in Study I by a statistician (J.B.) at 
Karolinska Institute. 
4.2.8 Ethical Considerations 
The Research Ethics Committee of Helsinki University Hospital (Study I-IV) and 
Karolinska University Hospital Huddinge (Study I) approved the studies. All 
participating patients and controls, or a parent in case of minors, signed a written 
informed consent form, in accordance with the Declaration of Helsinki (Studies II-
IV). 
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5 Results 
5.1 Ovarian Failure and Premature Menopause (I) 
Treatment characteristics of long-term female survivors after allogeneic HSCT in the 
Helsinki and Huddinge study are presented in Table 6 and Table 8. Patients were 
divided into three groups according to their pubertal status at HSCT. In the 
prepubertal group (n=70) pubertal status was Tanner 1, in midpubertal group (n=12) 
Tanner 2-3, and in postpubertal group (n=8) Tanner 4-5 at the time of HSCT. In 
Figure 12, the natural history of ovarian function during longitudinal follow-up after 
HSCT is described. 
 
Table 8. Characteristics of female long-term survivors after allogeneic HSCT. 
Characteristics (years) 
Study patients n=92 
Mean (range) 
Age at HSCT 9 (1-19) 
Age at last visit 22 (9-41) 
Follow-up time 13 (6-27) 
HSCT, hematopoietic stem cell transplantation 
 
Of the 70 girls who were prepubertal at HSCT, 30 showed no ovarian activity after 
HSCT. Forty prepubertal girls initiated spontaneous puberty, but 14 of them entered 
into premature menopause requiring estrogen substitution at a mean (±SD) age of 
17±3.2 years (range 13-25) at 11±4.4 years (6-21) after HSCT (Figure 12). In 
addition, three midpubertal girls temporarily recovered their ovarian function after 
HSCT (Figure 12). 
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Figure 12. Spontaneous onset of puberty (Sp) and menarche (Sm) and need of 
estrogen substitution (E2) at the latest follow-up visit defined by the 
pubertal status at the hematopoietic stem cell transplantation. NR, not 
relevant. 
Patients were classified into three groups according to the treatment they received 
before HSCT. The first group, leukemia group, consisted of AML (n=24) and ALL 
(n=33) patients. The second group consisted of patients with SAA (n=13) and the 
third group, others, was a heterogeneous group of patients with non-malignant 
disorders or malignant diseases without cytotoxic therapy given before HSCT 
conditioning. The incidence of spontaneous puberty and menarche and the use of 
estrogen substitution at the latest follow-up visit are presented in Table 9.  
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Table 9. Incidence of spontaneous puberty and menarche and use of estrogen 
substitution at the latest follow-up visit with total numbers of patients 
included in the evaluations in each group. 
 
Spontaneous 
puberty 
57%(n=40) 
% (Total n) P 
Spontaneous 
menarche 
45%(n=33) 
% (Total n) P 
No estrogen 
substitution 
34%(n=28) 
% (Total n) P 
Primary diagnosis (n=92) 
Leukemia 
(n=57) 
49(45)  33(45) 
<0.01 
30(54) 
<0.05 
SAA 
(n=13) 
75(8)  80(10) 67(11) 
Cranial radiotherapy (n=57) 
CRT- 
(n=45) 
57(35)  43(35) 
<0.01 
36(42)  
CRT+ 
(n=12) 
20(10)  0(10) 8(12)  
Remission status of leukemia patients (n=57) 
CR 1 
(n=28) 
61(23)  52(25) 
<0.005 
37(27)  
CR 2-4 
(n=29) 
36(22)  10(20) 22(27)  
Conditioning regimens 
TBI 
(n=71) 
53(53) <0.05* 35(54) <0.001* 29(68) <0.001* 
Busulfan 
(n=10) 
50(10) <0.05* 50(10) <0.05* 33(8) <0.01* 
Cy only 
(n=10) 
100(7)  100(8)  100(6)  
sTBI 
(n=29) 
52(21)  18(22) 
<0.05 
15(27)  
fTBI 
(n=42) 
53(32)  47(32) 39(41)  
CR, complete remission; CRT, cranial radiotherapy; Cy, cyclophosphamide; fTBI, fractionated total 
body irradiation; HSCT, hematopoietic stem cell transplantation; SAA, severe aplastic anemia; sTBI, 
single fraction total body irradiation; TBI, total body irradiation 
* compared with Cy. 
 
Patients with SAA showed higher incidence of spontaneous menarche (p<0.01) and 
they did not need estrogen substitution at their latest follow-up visit (p<0.05) when 
compared with the patients with leukemia. The girls who received only 
cyclophosphamide as conditioning experienced spontaneous puberty and menarche 
 53 
and there was no need for estrogen replacement therapy. Compared to those with 
sTBI, the girls who received fTBI experienced more often (p<0.05) spontaneous 
menarche. Leukemia survivors transplanted in the second or later remission and 
those who received CRT had lower incidence of spontaneous menarche than those 
transplanted in the first remission (p<0.005) and those with no CRT (p<0.01).  
Serum FSH levels were measured at the mean (±SD) age of 15±3.7 years (range 8-
30) and 7±4.9 years (0.1-21) after HSCT (Table 10). Leukemia patients had higher 
FSH levels than patients with SAA (p<0.05). Survivors with TBI or busulfan-based 
conditioning had higher levels of FSH compared to those with conditioning with 
only cyclophosphamide. 
Table 10. Serum FSH levels, measured 7 years after transplantation at a mean 
age of 15 years, from the pubertal or postpubertal period. 
 
FSH levels (IU/l)  
n=76 Mean±SD Range P 
Primary diagnosis  
Leukemia 48 43±36.5 1-160 <0.05* 
SAA 8 15±12.4 1-33 
Others 20 36±42.9 2-143  
Conditioning  
TBI 59 39±35.5 1-160 <0.05** 
Busulfan 10 57±48.3 3-143 <0.01** 
Cyclophosphamide 7 7±8.0 1-25  
HSCT, hematopoietic stem cell transplantation; SAA, severe aplastic anemia; TBI, total body 
irradiation 
* compared with SAA and ** compared with cyclophosphamide. 
 
Of the female survivors, ten (11%) women had given birth to 12 children and had 
had a total of 14 pregnancies at the mean (SD) age of 22±6.3 years (range 9-41). 
Four of the women with offspring had a diagnosis of leukemia and had received 
fTBI. Six of the mothers had a non-malignant diagnosis. One had received sTBI with 
ovarian shielding, three had received busulfan-based conditioning, and two 
cyclophosphamide-based conditioning. 
In bivariate logistic analysis, younger age at HSCT predicted spontaneous puberty 
(OR 1.2, 1.0-1.4, p=0.015). The SAA diagnosis (OR 6.1, 1.3-31.0, p=0.030), no 
TBI-based conditioning (OR 5.2, 1.6-16.5, p=0.006), no leukemia diagnosis (OR 
3.6, 1.3-9.7, p=0.011) and lower FSH serum level (OR 1.03, 1.01-1.06, p=0.002) 
predicted spontaneous menarche. The predictors for the need of estrogen substitution 
at the latest follow-up visit were sTBI (OR 4.3, 1.3-14.1, p=0.016) and no SAA 
diagnosis (OR 0.2, 0.1-0.9, p=0.033). 
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5.2 Cardiovascular Risk Factors and Blood Pressure (II-
IV) 
Clinical characteristics of the survivors of HR NBL and the age- and sex-matched 
healthy controls are presented in Table 11 (Study II- IV). Nineteen survivors and 
their sex- and age-matched healthy controls constituted the study population. Ten of 
the 19 survivors received TBI-based HDTx 10-12 Gy.  
 
Table 11. Clinical characteristics among the survivors of HR NBL and the 
controls. 
 
Controls 
(n=20) 
Mean±SD 
Survivors 
(n=19) 
Mean±SD P 
Survivors 
Non-TBI 
(n=9) 
Mean±SD 
Survivors 
TBI 
(n=10) 
Mean±SD P 
Age at study (years) 22.4±4.5 22.7±4.9 0.966 23.1±6.0 22.3±3.8 0.683 
Sex (M/F) 9/11 8/11 1.000 5/4 3/7 0.370 
Follow-up time 
(years) 
- 20.1±4.8 - 21.1±6.1 19.2±3.4 0.288 
Age at diagnosis 
(years) 
- 1.9±1.1 - 1.2±0.6 2.6±0.9 0.006 
Age at first HSCT 
(years) 
- 2.5±1.0 - 2.0±0.6 3.1±1.0 0.018 
Age at second HSCT 
(years) 
- 2.3±1.0 - 1.5 (n=1) 3.0 (n=1) 0.317 
DOXO (mg/m2) - 88±68 - 45±76 126±29 0.010 
Cisplatin (mg/m2) - 387±203 - 500±240 285±83 0.059 
DOXO, cumulative doxorubicin dose; HSCT, hematopoietic stem cell transplantation; TBI, total 
body irradiation 
 
Cardiovascular risk profiles and biochemical markers of frailty of the survivors and 
controls are described in (Table 12). The survivors’ height, weight and BSA were 
significantly smaller compared to the controls. Smoking was more common in the 
survivor group. Total cholesterol and triglycerides were significantly higher in the 
survivor group.  
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Table 12. Cardiovascular risk factors and markers of inflammation among the 
survivors of HR NBL and the controls (Study II-IV). 
 
Controls (n=20) 
Mean±SD 
Survivors (n=19) 
Mean±SD P 
Height (cm) 174±10 157±11 <0.001 
Weight (kg) 71.7±13.9 54.1±17.6 0.002 
BSA (m2) 1.9±0.2 1.5±0.3 <0.001 
BMI (kg/m2) 23.6±4.1 21.4±4.5 0.092 
Smoking (yes/no) 0/20 4/15 0.047 
fP-Cholesterol (mmol/L) 4.1±0.7 4.5±0.8 0.044 
fP-HDL (mmol/L)  1.5±0.3 1.6±0.4 0.844 
fP-Triglycerides (mmol/L) 0.9±0.4 1.3±0.6 0.017 
fP-Glucose (mmol/L) 5.1±0.3 5.3±0.5 0.129 
fP-GHbA1c (%) 5.1±0.2 5.5±1.1 0.100 
Pro-BNP (ng/L) 41± 30 128± 206 0.004 
S-hsCRP (mg/L) 2.6±7.8 3.5±3.2 0.002 
S-IGF-1 (nmol/L) 40±19 28±12 0.032 
BMI, body mass index; BSA, body surface area; GHbA1c, glycosylated hemoglobin A1c; IGF-1, 
insulin-like growth factor 1; Pro-BNP, N-terminal pro-brain natriuretic peptide; hsCRP, high-
sensitivity C-reactive protein; TBI, Total body irradiation; TNF, tumor necrosis factor 
 
No difference in glucose metabolism was observed between the survivors and the 
controls. We did not measure waist circumference so we were not able to evaluate all 
the criteria of metabolic syndrome in the survivor group, but the tendencies of other 
factors are presented in Table 13. One survivor was using treatment for diabetes and 
metabolic syndrome. 
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Table 13. Risk factors for metabolic syndrome in the survivors of HR NBL. 
Metabolic syndrome criteria* 
Survivors n=19 
n (%) 
SBP ≥ 130 or/ and DBP ≥ 85 or BP medication 9 (47) 
Triglycerides ≥ 1.7 mmol/L 2 (11) 
HDL < 1.0 mmol/L men, <1.3 mmol/L women 3 (16) 
Fasting glucose ≥ 5.6 mmol/L or medication 2 (11) 
Waist circumference (men/ women, > 100/90 cm) Not assessed 
Two ≥ criteria 5 (26) 
Three ≥ criteria 1 (5) 
The presence of three or more risk factors is required to fulfill the metabolic syndrome criteria in all 
five categories 
BP, blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; SBP, systolic 
blood pressure 
* According to harmonization study and joint statement (Alberti et al. 2009). 
 
The mean 24h systolic (24SYS%) (49% vs. 19%) and diastolic (24DIA%) (34% vs. 
17%) BP loads were significantly higher (p<0.001, p=0.040) in the survivors 
compared to the controls. Daytime systolic and diastolic loads and nighttime systolic 
load were also significantly higher among the survivors (Table 14).  
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Table 14. Twenty-four-hour ambulatory blood pressure profiles in the survivors 
of HR NBL and the controls. 
BP, blood pressure 
 
5.3 Arterial Intima Thickening and Plaque Formation (II) 
Arterial measurements are presented in Table 15. The survivors had smaller brachial 
and femoral lumen diameters when compared to the control group. Carotid IMT was 
increased among the survivors. Local plaques were found in three survivors treated 
with TBI in the carotid bulb or in the common femoral artery. A double line 
appearance at the lumen-intima interface in the radial artery was displayed in five 
survivors and at the common femoral artery in two. The TBI-treated survivors 
displayed smaller arterial LDs in brachial (p=0.004), radial (p=0.004) and femoral 
(p=0.018) arteries and increased carotid artery IMT (p=0.004) when compared to the 
non-TBI survivors. 
 
 
 
Blood pressure Controls (n=20) Survivors (n=19)  
Mean 24h BP Mean±SD Mean±SD P 
Systolic BP (mmHg) 122±10 129±14 0.083 
Diastolic BP (mmHg) 70±6 75±12 0.237 
Systolic load (%) 19±17 49±29 <0.001 
Diastolic load (%) 17±15 34±30 0.040 
Patients with systolic load ≥25% (n) 3 13 0.001 
Patients with diastolic load ≥25% (n) 4 8 0.176 
Mean daytime BP 
Systolic BP (mmHg) 126±10 133±15 0.164 
Diastolic BP (mmHg) 74±6 79±12 0.118 
Systolic load (%) 19±17 48±30 0.001 
Diastolic load (%) 17±15 35±30 0.034 
Patients with systolic load ≥25% (n) 3 14 <0.001 
Patients with diastolic load ≥25% (n) 5 10 0.105 
Mean night-time BP 
Systolic BP (mmHg) 111±10 122±16 0.019 
Diastolic BP (mmHg) 61±5 66±12 0.278 
Systolic load (%) 19±19 57±37 0.001 
Diastolic load (%) 18±20 34±38 0.267 
Patients with systolic load ≥25% (n) 7 14 0.010 
Patients with diastolic load ≥25% (n) 5 8 0.320 
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Table 15. Arterial measurement in the HR NBL survivors and the controls. 
 
Control 
n=20 
Mean±SD 
Survivor 
n=19 
Mean±SD P 
Arterial lumen diameters 
BALDD (mm) 7.27±0.96 5.82±0.72 <0.001 
FALDD (mm) 3.21±0.52 2.80±0.49 0.017 
Arterial morphology 
CCAIMT (mm) 0.41±0.04 0.47±0.09 0.035 
PLAQUE (yes/no) 0/20 3/16 0.106 
RAIDL (yes/no) 0/20 5/14 0.020 
FAIDL (yes/no) 0/20 2/17 0.231 
Carotid artery stiffness 
CACOMP 
(%/10mmHg) 
3.35±0.68 2.65±0.62 0.002 
CASTIF 3.50±0.73 4.13±0.69 0.013 
CACOMP, Common carotid artery compliance; CASTIF, Common carotid artery stiffness index; 
CCAIMT, Common carotid artery intima-media thickness; BALDD, Brachial artery lumen diameter 
in end-diastole; FAIDL, Femoral artery intima double layer; FALDD, Femoral artery lumen diameter 
in end-diastole; PLAQUE, Arterial plaque; RAIDL, Radial artery intima double layer 
 
Carotid artery compliance was decreased and carotid artery stiffness increased 
among the survivors when compared to the controls.  
To evaluate associations between vascular parameters and cardiovascular risk factors 
and treatments, and to adjust differences in BSA and cardiovascular risk factors 
between the survivors and the controls and the TBI and non-TBI groups, simple and 
multiple linear regressions were performed. TBI treatment and low BSA were 
identified as independent predictors of small arterial lumen diameter and increased 
carotid IMT among the survivors. Triglycerides and 24SYS were independently 
associated with carotid IMT. The cumulative doxorubicin dose was not significantly 
associated with vascular parameters in multiple linear regression analyses. 
Triglycerides were associated with carotid compliance in simple linear regression 
analysis. 
In the FMD analyses, we found no significant differences between the survivors and 
the controls (10.2% vs. 9.6%) or between TBI and non-TBI survivors (13% vs. 8%). 
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5.4 Left Ventricular Hypertrophy and Cardiac Dysfunction 
(III) 
5.4.1 Left Ventricular Mass 
3DE LVMI was significantly higher in the survivor group when compared to the 
controls (Table 16). When it was adjusted to the ESV the difference was more 
evident. Three (16%) HR NBL survivors presented LV hypertrophy >2SD when 
LVMI was compared to the control group. End-diastolic volume (EDV) was 
significantly decreased in the subgroup of survivors who had received TBI when 
compared to those without TBI (41.1mL vs. 48.5mL, p=0.004). 
 
Table 16. 3DE LVM and volume analyses in HR NBL survivors and controls. 
 
Controls 
(n=20) 
Mean±SD 
Survivors 
(n=19) 
Mean±SD P 
Survivors 
Non-TBI 
(n=9) 
Mean±SD 
Survivors 
TBI 
(n=10) 
Mean±SD P 
3D ESV/m2 (mL) 19.4±6.3 18.3±3.9 0.431 19.0±4.4 17.7±3.6 0.568 
3D EDV/m2 (mL) 50.6±15.2 44.6±6.6 0.092 48.5±3.9 41.1±6.8 0.004 
3D LVMI (g/m2.7) 28.1±4.7 33.9±9.7 0.038 34.3±10.5 33.6±9.4 0.935 
3D LVMI/ESV 
(g/m2.7mL) 
0.9±0.5 1.3±0.7 0.006 1.2±0.5 1.5±0.8 0.369 
EDV, end-diastolic volume; ESV, end-systolic volume; LVMI, left ventricular mass index; TBI, total 
body irradiation 
 
LVMI correlated positively with 24SYS (r=0.465, p=0.003) and with serum 
triglycerides (r=0.444, p=0.005) when adjusted to ESV. 24SYS (p=0.024) and being 
a HR NBL survivor (p=0.020) were shown to be predictors of increased LVMI in 
simple linear regression analyses, but no independent predictive effect was found 
when they were entered in multiple linear regression analysis.  
5.4.2 Left Ventricular Function 
Abnormal 3DE LV EF <50% (Armstrong et al. 2015) as a sign of systolic 
dysfunction was observed in 10.5% of the patients and abnormal diastolic function in 
15.8% (TDI E/E’>15) (Lipshultz et al. 2013). All of the controls had normal systolic 
and diastolic functional measurements. Cardiac function results are described in 
Table 17. Systolic function was significantly decreased (TDI S’) among the 
survivors compared to the controls (7.5 cm/s vs. 9.3 cm/s, p=0.006) and the TBI-
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treated survivors had the lowest function when compared to the non-TBI group (6.8 
cm/s vs. 8.2 cm/s, p=0.041). The same result was found in the diastolic function 
(TDI E/E’, Table 17). No difference was detected in 3D synchronization indexes 
between the survivors and the controls (Table 17). LVMI correlated with both 
decreased systolic (TDI S’, r=-0.335, p=0.037) and diastolic function (TDI E/E’, 
r=0.440, p=0.005). 
 
Table 17. Left ventricular function in HR NBL survivors and controls. 
 
Controls 
(n=20) 
Mean±SD 
Survivors 
(n=19) 
Mean±SD P 
Survivors 
Non-TBI 
(n=9) 
Mean±SD 
Survivors 
TBI 
(n=10) 
Mean±SD P 
Systolic function 
3DE EF (%) 61.8±6.9 58.7±7.5 0.191 60.8±7.7 56.7±7.1 0.253 
3DE SV/m2 
(mL/m2) 
31.2±10.1 26.3±5.6 0.092 29.5±4.4 23.4±5.1 0.018 
TDI S’ (cm/s) 9.3±2.0 7.5±1.4 0.006 8.2±1.2 6.8±1.4 0.041 
Diastolic function 
TDI E' (cm/s) 13.2±2.1 10.9±2.0 0.003 11.9±1.4 10.0±2.1 0.041 
TDI E/E’ 8.0±1.8 11.2±3.8 0.003 9.0±1.8 13.2±4.1 0.022 
Synchronization 
3DE 16DSI 1.9±1.1 2.5±1.7 0.346 2.7±2.3 2.2±0.9 0.870 
16SDI, 16 segments Systolic Dyssynchrony Index; 3DE, 3 dimensional echocardiography; E, Mitral 
peak velocity in early diastole; E’, Early diastolic peak mitral annular velocity; EF, Ejection fraction; 
S’, Peak myocardial sustained systolic velocity; SV, Stroke volume; TBI, Total body irradiation; TDI, 
Tissue Doppler Imaging 
 
Cardiac analysis of one HR NBL patient is presented in Figure 9 and Figure 10. The 
analysis showed decreased systolic (3D EF 51%, TDI S’ 4.6 cm/s) and diastolic 
function (TDI E/E’ 19.6). No dyssynchrony  (16 SDI 2%) was detected. The heart 
was hypertrophic  (LVMI 36 g/m2.7, 1.63SD) due to the hypertension. The patient’s 
physical performance was poor and less than half a year after the study the patient 
died. Autopsy revealed pancreatitis as cause of death. The patient also had 
pathological coronary artery disease. 
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5.4.3 Physical Performance 
The survivors of HR NBL showed poor physical performance when compared to the 
controls. Survivors performed significantly poorer in all but the leg-lift test 
(p=0.058) (Figure 13). 
  
Figure 13. Physical performance tests: (A) leg lift, (B) repeated squatting, (C) sit-
up, (D) back extension, (E) shuttle run and (F) muscle sum score 
compared between controls and HR NBL survivors. 
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5.5 Accelerated Aging and Frailty Phenotype (IV) 
Clinical characteristics of the survivors of HR NBL and the controls are described in 
Table 11 and body composition, life-style habits and physical condition in Table 18. 
The survivors had significantly lower total body lean mass, higher fat mass 
percentage and higher trunk fat percentage when compared to the controls. No 
difference in BMI was observed but BSA was smaller in the survivor group. The 
survivors reported lower frequency, intensity and duration of physical activities 
when converted to kilocalories expended per week. They were slower in the shuttle 
run test and the number of sit-ups was lower when compared to the controls. 
 
 
Figure 14. Twenty-seven-year-old high-risk neuroblastoma survivor who met four 
criteria of frailty phenotype. 
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Table 18. Characteristics of body composition, life-style habits, physical 
condition and telomere length in the HR NBL survivors and the 
controls. 
Characteristic 
Survivors Controls 
P Mean±SD Range Mean±SD Range 
Anthropometric measurement 
Lean mass (kg) 36.2±12.1 16.8-70.2 53.8±12.3 33.7-78.3 <0.001 
Lean mass/height2 (kg/m2) 14.3±2.9 9.6-22.4 17.6±2.7 12.2-24.0 <0.001 
Fat mass (kg) 16.5±7.1 3.7-29.8 15.8±6.6 6.5-29.5 0.667 
Fat mass % 27.6±8.9 3.8-39.7 21.9±8.0 10.3-36.3 0.030 
Trunk fat mass % 24.6±8.8 3.6-39.4 17.5±8.0 3.6-33.5 0.015 
Life-style habits and physical condition 
Total kcal expended per week 496±595 0-2338 1592±1337 0-5468 <0.001 
Shuttle run (time in seconds 
spent for 10x5m) 
30.5±10.6 21.0-60.1 20.6±1.7 17.3-24.1 <0.001 
Sit-ups (per 30 second) 10±8 0-23 20±6 2-28 <0.001 
Telomere length (AU) 0.67±0.38 0.24-1.73 1.00±0.65 0.25-3.08 0.044 
AU, arbitrary unit 
 
Prevalence of the frailty phenotype was 9/19 and pre-frailty phenotype 2/19 among 
the survivors. None of the age- and sex-matched healthy controls presented a pre-
frailty or frailty phenotype. Relations of frailty phenotypes with demographic 
characteristics, lifestyle habits, self-reported chronic conditions, medical treatments, 
physical health limitations, and markers of frail health are presented in Table 19.  
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Table 19. Characteristics by frailty phenotype in 19 survivors and 20 controls. 
Characteristic 
Non-frail 
n=28 
Frail or pre-frail 
n=11 
P n % n % 
Current smoker 1 3.6 3 27.3 0.060 
Exposure to TBI 3 10.7 7 63.6 0.002 
Estrogen/testosterone substitution 3 10.7 9 81.8 <0.001 
Physical health limitations 
Vigorous activities (lifting heavy 
objects, running, strenuous sports) 
4 14.3 9 81.8 <0.001 
Moderate activities (pushing a 
vacuum cleaner, moving a table, 
carrying groceries) 
0 0 3 27.3 0.018 
Walking a few hundred meters 0 0 3 27.3 0.018 
Potential markers of frail health Median Range Median Range P 
BSA (m2) 1.8 1.3-2.3 1.4 0.9-2.0 <0.001 
Telomere length (AU) 0.81 0.24-3.08 0.46 0.24- 1.25 0.077 
S-hsCRP (mg/L) 0.71 0.11-34.46 3.76 0.26- 11.39 0.005 
24h mean heart rate (beats /min) 74 52-99 82 61-90 0.038 
BALDD (mm) 3.04 2.22-4.34 2.55 2.21-3.29 0.011 
FALDD (mm) 6.73 5.11-9.21 5.79 4.61-7.40 0.014 
CAIMT (mm) 0.43 0.34-0.55 0.47 0.35-0.72 0.083 
Radial artery intima double layer, n 1  4  0.017 
Arterial plaque, n 1  2  0.187 
U-Albumin/creatinine ratio 
(mg/mmol) 
0.3 0.1-24.1 1.6 0.5-104.5 0.001 
S-IGF-1 (nmol/L) 38 12-90 24 14-44 0.029 
AU, arbitrary unit; BALDD, brachial artery lumen diameter in end-diastole; BSA, body surface area; 
CAIMT, common carotid artery intima-media thickness; FALDD, femoral artery lumen diameter in 
end-diastole; hsCRP, high sensitivity C-reactive protein; IGF-1, insulin-like growth factor 1; TBI, 
total body irradiation 
 
 
Frailty phenotype was associated with increased frequency of physical activity 
limitations such as inability to walk a few hundred meters. Frailty/pre-frailty 
phenotype was associated with an increased resting heart rate, decreased femoral and 
brachial artery LDs and the presence of intima double-line layer, but not with LVM 
or LV function. 
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Telomere length correlated significantly with GHbA1c (r=0.331, p=0.043), IGF-1 
(r=0.361, p=0.026) and hsCRP (r=-0.385, p=0.017). Simple and multiple linear 
regression analyses identified low IGF-1 (p=0.010) and low GHbA1c (p=0.007) as 
independent predictors of decreased telomere length.  
The survivors presented significantly higher levels of hsCRP when compared to the 
controls and the frailty/pre-frailty phenotype compared to the non-frailty phenotype. 
Increased hsCRP correlated with several adverse cardiovascular risk factors 
including triglycerides (r=0.516, p=0.001), subclinical atherosclerotic findings 
(carotid IMT, r=0.511, p=0.001), and systolic (TDI S’, r=-0.0358, p=0.027) and 
diastolic function (TDI E/E’, r=0.387, p=0.016) of LV. HsCRP correlated also with 
increased fat mass (fat mass %, r=0.403, p=0.012), decreased lean mass (lean 
mass/height2, r=-0.324, p=0.047), decreased total kcal expended per week (r=-0.565, 
p<0.001) and decreased performance in physical tests such as shuttle run test 
(r=0.494, p=0.002) and sit-ups (r=-0.441, p=0.006).  
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6 Discussion 
6.1 Early Ovarian Aging and Premature Menopause after 
Pediatric Allogeneic HSCT (I) 
In the present study, declining ovarian function was associated with older age at 
HSCT. More than half of the survivors showed no ovarian activity after HSCT, 
suggesting that the entire follicle pool was depleted at the time of HSCT. In the 
previous studies, very young survivors with larger ovarian reserves have had better 
changes to at least temporarily recover their ovarian function after HSCT. The 
present observations are in line with these studies (Sanders et al. 1988, Spinelli et al. 
1994, Borgmann-Staudt et al. 2012). 
At their latest follow-up visit, 41 of the young women who were prepubertal, 11 of 
those 12 who were midpubertal and three of the eight who were postpubertal at the 
time of HSCT needed estrogen replacement therapy. Most of these survivors showed 
no ovarian activity after HCST. After HSCT, 14 prepubertal girls and two 
midpubertal girls temporarily recovered their ovarian function but entered premature 
menopause. The identification of these survivors with residual ovarian function is a 
major challenge because there might be a short-term benefit from fertility 
preservation techniques (Das et al. 2012, Socie et al. 2003).  
Compared to survivors conditioned with cyclophosphamide only, female survivors 
conditioned with TBI, especially sTBI, or busulfan were at higher risk for premature 
menopause. Leukemia survivors who received CRT for anti-leukemia therapy before 
HSCT or were transplanted after disease relapse were at increased risk for permanent 
ovarian failure. From previous studies it is known that >30 Gy CRT is damaging to 
the hypothalamic pituitary region resulting in gonadotropin-releasing hormone 
deficiency (Cohen et al. 2008). In our study, female survivors who had received 
CRT at doses of 14-24 Gy had high menopausal serum levels of FSH and presented 
no signs of hypogonadotrophic hypogonadism.  
At a mean age of 22 years, ten women had become pregnant. One survivor became 
pregnant after ovarian shielding, which confirms that this method during TBI 
potentially protects the ovary from irradiation damage (Nakagawa et al. 2006). 
Female survivors transplanted at a young age with allogeneic HSCT are at high risk 
for early ovarian aging. Older age at HSCT, TBI- and/or busulfan-based 
conditioning increase the risk considerably. Girls need to be followed up regularly so 
that a possible window of ovarian recovery can be detected. 
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6.2 Early Vascular Aging after Pediatric HSCT (II) 
Increased stiffness of the arteries has been reported as a hallmark of early vascular 
aging (Nilsson 2014). The long-term survivors of HR NBL presented increased 
arterial stiffness, intima thickening, and frequent plaque formation at a mean age of 
22.7 years. The prevalence of plaques (19%) was similar to that in the general 
population for males over 40 and women over 50 (Joakimsen et al. 1999). All these 
findings are indicative of significant early vascular aging after therapy for HR NBL. 
TBI was an independent predictor for the development of atherosclerotic vascular 
changes after therapy for HR NBL. In adults, obstruction of the arterial lumen 
(Carmody et al. 1999, Sutton et al. 2009), radiation dose-dependent IMT thickening 
(Feehs et al. 1991, Dorresteijn et al. 2005, Shariat et al. 2008, Gianicolo et al. 2010) 
and advanced accelerated carotid artery disease have been reported after local RT 
(Silverberg et al. 1978). Childhood cancer survivors, especially pediatric CNS tumor 
survivors and survivors of Hodgkin’s disease, have shown increased carotid and 
femoral IMT (Dengel et al. 2014, Brouwer et al. 2013, Meeske et al. 2009), coronary 
artery disease (Kupeli et al. 2010) and increased occurrence of stroke after 
irradiation therapy (Bowers et al. 2006, Mueller et al. 2013, Bowers et al. 2005).  
Previous studies with pediatric CNS tumor survivors have reported a radiation dose 
above 30 Gy as a threshold for an increased occurrence of stroke (Bowers et al. 
2006). Radiation doses of more than 20 Gy have been associated with the 
development of coronary artery disease among survivors with Hodgkin lymphoma 
(Kupeli et al. 2010). Early mechanical changes such as decreased distensibility of the 
carotid arterial wall have been described after TBI-based conditioning for pediatric 
HSCT with doses of 10-14 Gy after a minimum of two years’ follow-up time 
(Turanlahti et al. 2013). The present study shows that even lower irradiation 
exposures of 10-12 Gy as part of HSCT conditioning are able to induce vascular 
damage that can be detected after a long-term follow-up of 20 years.  
The previous studies have shown that subclinical atherosclerotic changes in the 
carotid artery reflect more generalized atherosclerotic pathology (Neunteufl et al. 
1997). In our study, common carotid, brachial, radial and femoral arteries were 
examined with highest 25/35/55 MHz frequency transducers since ultrasound 
penetrance limits the use of the highest frequencies in the non-invasive assessment 
of the more deeply located proximal arteries. We were able to detect a double line 
appearance in the proximity of the lumen-intima interface in five of the survivors. 
The double line appearance was interpreted as intima thickening. All survivors with 
plaques also had double line appearance. 
The significantly increased cardiovascular risk profile in the HR NBL survivors is 
likely to play a minor role in the vascular findings observed as no difference in 
6 Discussion 
68 
cardiovascular risk factors was observed between TBI and non-TBI survivors. 
However, systolic BP emerged as an independent predictor for increased carotid 
IMT. The identification of cardiovascular risk factors together with the adverse 
effects of irradiation stresses the importance of monitoring these emerging 
subclinical organ dysfunctions that may impact the early vascular aging observed 
among long-term childhood cancer survivors. 
6.3 Hypertension and Left Ventricular Hypertrophy after 
Pediatric HSCT (III) 
The adult and adolescent very long-term survivors of HR NBL presented increased 
LVM, which was associated with decreased systolic and diastolic LV function, 
increased cardiac biomarkers and poor physical performance. Systolic BP was 
associated with LVM, suggesting a role in the development of LV hypertrophy in 
long-term survivors.  
The use of anthracyclines is known to be a contributing factor, and a combination of 
anthracyclines and chest irradiation increases the risk of developing congestive heart 
failure (Lipshultz et al. 2013). In previous studies, there has been only a little 
evidence of increased risk of heart failure with chest irradiation with doses below 15 
Gy (Armenian et al. 2015). In the present study, the survivors treated with TBI 10-12 
Gy and moderate dose of anthracyclines (100-250mg/m2) (Armenian et al. 2015) 
presented the most remarkable changes in cardiac function. The TBI-treated 
survivors showed smaller EDV, increased LVM and increased TDI E/E’, suggesting 
restrictive physiology. Diastolic dysfunction has been associated with radiation-
induced cardiotoxicity in previous studies (Alehan et al. 2012). Increased serum pro-
BNP levels and heart rate among survivors supported the findings of cardiac 
dysfunction in the present study. Increased serum pro-BNP is used as a biomarker 
for the diagnosis of symptomatic heart failure (Braunwald 2008). The observed 
increased heart rate is known to be a risk factor for sudden death and an indicator of 
autonomic dysfunction (King et al. 2006).  
The survivors had higher plasma levels of triglycerides and cholesterol, higher 
incidence of smoking, higher BP and poorer physical performance than the control 
group. Most of these cardiovascular risk factors are known to increase when people 
enter middle age. Early intervention may reduce the risk of premature cardiac 
disease. Cardiovascular risk factors should be routinely screened during the follow-
ups of the survivors. 
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6.4 Frailty after Pediatric HSCT (IV) 
Adult and adolescent long-term survivors of HR NBL showed a high frequency of 
frailty phenotype when compared to their age-matched controls, suggesting 
accelerated aging. Frailty phenotype associated with poor cardiovascular health.  
The prevalence of frailty phenotype in the survivors of HR NBL was 47.4% while 
combined prevalence of frailty and pre-frailty was 57.9%. In previous studies, a 
26.1% prevalence of frailty has been reported among community-dwelling elderly 
persons over 85 years of age (Collard et al. 2012). In the present study, the survivors 
at a mean age of 22 years had higher prevalence of frailty than elderly persons over 
85 years (Collard et al. 2012). This suggests significantly advanced aging. Combined 
frailty phenotype in the present survivor cohort was also higher when compared to 
results from the St Jude Lifetime Cohort Study among survivors of CNS tumors 
(41.2%), soft tissue sarcomas (39.4%), other solid tumors (38.7%) and leukemia, 
lymphoma and bone tumors (30%) (Ness et al. 2013). 
In the present study, telomere length was significantly shorter among the survivors 
compared to the age- and sex-matched healthy controls. Telomere shortening 
accelerates in replicative proliferative tissues when tissue is exposed to 
inflammation, oxidative stress, radiation or toxins, leading to cellular senescence and 
the process of aging (Shay & Wright 2007). Telomere shortening has also been 
associated with chronic somatic diseases of aging (Shay & Wright 2007). In our 
study, we could not associate telomere length with frailty phenotype. Instead, we 
found that low IGF-1 was an independent predictor of shorter telomere length. Short 
telomere length that associates with poor growth hormone status (Chemaitilly et al. 
2015) may be partly explained by exposure to CRT. Low GHbA1c was also an 
independent predictor of shortened telomere length. Low GHbA1c is known to be a 
marker of increased mortality among diabetic patients and a marker of poor nutrition 
in frail persons without diabetes (Abdelhafiz & Sinclair 2015). Childhood cancer 
survivors have hormonal impairments, poor nutritional intake and poor physical 
activity, all of which can together lead to lower lean mass, physical weakness, low 
activity levels and slowness. Association of poor nutritional status with frail health 
may explain the connection between low GHbA1C and short telomere length. 
The frailty phenotype in our study identified HR NBL survivors at risk for poor 
cardiovascular health. The frailty phenotype was associated with increased resting 
heart rate, which is known to be an independent risk factor for sudden death in adults 
(Kannel et al. 1987). Frailty was also associated with decreased femoral and brachial 
artery diameters in end-diastole and the appearance of intima double-line layer, 
suggesting subclinical atherosclerosis. 
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The frail survivors presented an increased prevalence of hypogonadism requiring 
hormonal replacement therapy and lower levels of IGF-1. These results are in line 
with a previous study where exposure to CRT and abdominal/pelvic irradiation 
associated with frail health (Ness et al. 2013). Anterior pituitary deficits, including 
growth hormone deficiency, are common after CRT with doses exceeding 22 Gy 
(Chemaitilly et al. 2015). High-risk gonadal toxicity is known to associate with 
HDTx and conditioning with TBI (Vatanen et al. 2013, Wilhelmsson et al. 2014). In 
this study, 52.7% of frail/pre-frail survivors had received TBI 10-12 Gy, and three 
had received 20-32 Gy doses to the cranial area. In line with a previous study, 
gonadal deficiency was not limited to survivors exposed to TBI (Chemaitilly et al. 
2015). Accordingly, more than 80% of the frail survivors presented gonadal 
deficiency in this study, and 63% of them were exposed to TBI. 
In this study, hsCRP correlated with frailty phenotype and was associated with 
increased percentage of fat mass, decreased lean mass, decreased total kcal expended 
per week, decreased performance in physical performance tests, several 
cardiovascular risk factors and measures of subclinical atherosclerosis and decreased 
LV function. Our findings are well in line with previous studies where sterile 
inflammation and elevated circulating CRP associated with early arterial changes 
(Jarvisalo et al. 2002), physical disability (Adriaensen et al. 2014), low lean mass 
and obesity (Cesari et al. 2005, Wang et al. 2011). Our findings support the 
hypothesis that inflammation plays a role in the pathogenesis of early vascular aging 
(Jarvisalo et al. 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 71 
6.5 Strengths and Limitations of the Study 
(Study I) The study with two hospital cohorts of female long-term survivors of 
pediatric allogeneic HSCT is limited by the young age of survivors and the lack of 
possibility to evaluate the wish to become pregnant. This information would have 
been needed to analyze the precise incidence of fertility after HSCT. The small 
number of leukemia survivors treated without TBI also limited us to evaluate the 
effects of previous CRT and relapsed disease on ovarian function in this patient 
group. 
The major strength of this study was the longitudinal follow-up into puberty and 
adulthood of a well-defined cohort of girls and young women after pediatric 
allogeneic HSCT that made it possible to identify girls with temporary recovery of 
ovarian function. 
(Study II-IV) Studies of a national cohort of HR NBL survivors were limited by the 
small sample size, while 79% of the national cohort was enrolled. The small sample 
size is mainly attributable to the poor prognosis of HR NBL patients in the previous 
decades. 
The small sample size may have precluded statistically significant differences 
between groups in endothelial function and might also pose some limitations in the 
interpretation of the multiple linear regression analyses. Conventional treatment and 
specific chemotherapeutic agents varied over time; as a result, we failed to link 
cardiovascular changes to specific chemotherapeutics. The TBI-conditioned 
survivors also received higher cumulative doses of doxorubicin than the non-TBI 
survivors. The cumulative doses among the survivors were, however, low (Armenian 
et al. 2015) (91 mg/m2 (0-210)) and are unlikely to explain the vascular differences 
between the TBI and the non-TBI survivors. Previous reports have found 
associations between endothelial dysfunction and anthracyclines (Herceg-Cavrak et 
al. 2011) but some have failed to show significant associations between 
anthracyclines and atherosclerosis when anthracyclines were combined with RT 
(King et al. 1999). 
Major strengths of the study include the population-based design, extended follow-
up from early childhood to young adulthood, comprehensive cardiovascular 
assessment with novel vascular ultrasound technology VHRU and novel 3D 
echocardiography, and the comprehensive set of metabolic cardiovascular risk and 
physiologic factors, telomere length and inflammatory markers linked to the frailty 
and pre-frailty phenotypes. 
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6.6 Future Considerations 
(Study I) The identification of the patient group who temporarily recover their 
ovarian function after HSCT is a major challenge in the future in terms of fertility 
counseling and fertility preservation after transplantation. The period of recovery can 
be identified only with regular follow-up. 
(Study II-IV) Future studies will need to address cardiovascular risk factors, early 
vascular aging, LVM and LV function and frailty among other patient groups 
exposed to TBI and other conditioning therapies in larger cohorts. It is also 
important to further evaluate the possible additive adverse effect of previous cancer 
therapy prior to HSCT on these parameters.  
These results advocate a more comprehensive long-term follow-up with detection 
and intervention for cardiovascular risk factors in survivors after pediatric HSCT. 
Increased LVM and early vascular aging, as well as the observed systolic and 
diastolic cardiac dysfunction emphasizes the importance of assessing cardiovascular 
parameters in the clinical follow-up in order to facilitate early detection of 
subclinical disease and interventions to reduce the impact of common cardiovascular 
risk factors in the long term. Since lifestyle choices can influence cardiovascular 
health, frailty status and early vascular aging, a healthy lifestyle, non-smoking, low-
fat diet and physical activity should be advocated among all survivors after HSCT. 
Survivors should be encouraged to rehearse speed and muscle strength in order to 
maintain their muscle mass to prevent the progression of premature aging and frailty. 
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7 Conclusions 
 
The main conclusions of this thesis are: 
 
Study I 
Girls and young women conditioned with TBI or busulfan regimens prior to 
allogeneic HSCT in childhood are at high risk of premature ovarian aging including 
permanent ovarian failure and premature menopause. The use of CRT for anti-
leukemia therapy before HSCT further decreases the possibility of spontaneous 
menarche. 
Study II 
The adolescent and young adult long-term survivors of HR NBL treated in early 
childhood with HSCT including TBI show signs of early vascular aging. Arterial 
plaques were found in three survivors treated with TBI and thickened intima layer in 
four TBI-treated and one non-TBI-treated survivor. Carotid IMT and stiffness were 
increased and compliance decreased among the survivors. Brachial and femoral 
lumen diameters were smaller among the survivors. The survivors displayed higher 
levels of plasma cholesterol and triglycerides, and smoking was more common 
compared to the control group. 
Study III 
The HR NBL survivors treated with HSCT in early childhood show signs of 
increased LVM when compared to the age- and sex-matched healthy controls. The 
survivors’ systolic and diastolic LV function was decreased. The increase in cardiac 
biomarkers and poor physical performance support these findings. Taken together, 
the increased LVM and decreased EDV suggest possible myocardial fibrosis-related 
restriction among the TBI-treated survivors. There was association with 24SYS and 
LVM suggesting an important role of BP in the development of LV hypertrophy and 
long-term cardiovascular health in these patients. 
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Study IV 
Frailty phenotype, including decreased muscle mass, slowness, weakness, 
exhaustion and low physical activity, is prevalent after HSCT and suggests 
significantly accelerated aging. The frailty phenotype identifies survivors at risk of 
poor cardiovascular health. Chronic inflammation correlates with frailty phenotype, 
increased percentage of fat mass, decreased lean mass, decreased total kcal expended 
per week, decreased performance in physical performance tests and cardiovascular 
health. The survivors of HR NBL treated with HSCT in early childhood have shorter 
telomere length when compared to the healthy age- and sex-matched controls. 
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